المؤلفون: A. S. Elgouhari, N. M. Lazareva, O. P. Baranova, I. V. Kudryavtsev, T. P. Ses, M. M. Ilkovich, A. A. Totolian, А. С. Эльгухари, Н. М. Лазарева, О. П. Баранова, И. В. Кудрявцев, Т. П. Сесь, М. М. Илькович, А. А. Тотолян

المساهمون: Работа выполнена при поддержке гранта РНФ № 22-24-20013.

المصدر: Medical Immunology (Russia); Том 26, № 4 (2024); 755-764 ; Медицинская иммунология; Том 26, № 4 (2024); 755-764 ; 2313-741X ; 1563-0625

مصطلحات موضوعية: фиброз, Löfgren’s syndrome, Th17 cell, Treg, biomarker, IL-17A, granuloma, fibrosis, синдром Лефгрена, Т-хелперы 17-го типа, Т-регуляторные клетки, биомаркер, гранулема

وصف الملف: application/pdf

Relation: https://www.mimmun.ru/mimmun/article/view/3046/1973; Зурочка А.В., Хайдуков С.В., Кудрявцев И.В., Черешнев В.А. Проточная цитометрия в биомедицинских исследованиях. Екатеринбург: Уральское отделение РАН, 2018. 720 с.; Кудрявцев И.В., Лазарева Н.М., Баранова О.П., Серебрякова М.К., Сесь Т.П., Илькович М.М., Тотолян А.А. Особенности «поляризации» Т-хелперов периферической крови при остром и хроническом саркоидозе. // Медицинская иммунология, 2022. Т. 22, № 3. С. 573-586. doi:10.15789/1563-0625-PBT-2468.; Bettelli E., Carrier Y., Gao W., Korn T., Strom T.B., Oukka M., Weiner H.L., Kuchroo V.K. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature, 2006, Vol. 441, pp. 235-238.; Broos C.E., Hendriks R.W., Kool M. T-cell immunology in sarcoidosis: Disruption of a delicate balance between helper and regulatory T-cells. Curr. Opin. Pulm. Med., 2016, Vol. 22, no. 5, pp. 476-483.; Capone A., Volpe E. Transcriptional regulators of T helper 17 cell differentiation in health and autoimmune diseases. Front. Immunol., 2020. Vol. 11, 348. doi:10.3389/fimmu.2020.00348.; Hunninghake G.W., Costabel U., Ando M., Baughman R., Cordier J.F., du Bois R., Eklund A., Kitaichi M., Lynch J., Rizzato G., Rose C., Selroos O., Semenzato G., Sharma O.P. ATS/ERS/WASOG statement on sarcoidosis. American thoracic society/European respiratory society/world association of sarcoidosis and other granulomatous disorders. Sarcoidosis Vasc. Diffuse. Lung. Dis., 1999, Vol. 16, no. 2, pp. 149-173.; Kudryavtsev I., Zinchenko Y., Starshinova A., Serebriakova M., Malkova A., Akisheva T., Kudlay D., Glushkova A., Yablonskiy P., Shoenfeld Y. Circulating regulatory T cell subsets in patients with sarcoidosis. Diagnostics, 2023. Vol. 13, no. 8, 1378. doi:10.3390/diagnostics13081378.; Lazareva N.M., Kudryavtsev I.V., Baranova O.P., Isakov D.V., Serebriakova M.K., Bazhanov A.A., Arsentieva N.A., Liubimova N.E., Ses’ T.P., Ilkovich M.M., Totolian A.A. Sarcoidosis clinical picture governs alterations in type 17 T helper cell subset composition and cytokine profile. Medical Immunology (Russia), 2023, Vol. 25, no. 5, pp. 1049-1058. doi:10.15789/1563-0625-SCP-2694.; Polverino F., Balestro E., Spagnolo P. Clinical presentations, pathogenesis, and therapy of sarcoidosis: state of the art. J. Clin. Med., 2020, Vol. 9, no. 8, 2363. doi:10.3390/jcm9082363.; Schnell A., Littman D.R., Kuchroo V.K. TH17 cell heterogeneity and its role in tissue inflammation. Nat. Immunol., 2023. Vol. 24, no. 1, pp. 19-29.; Shigehara K., Shijubo N., Ohmichi M., Takahashi R., Kon S., Okamura H., Kurimoto M., Hiraga Y., Tatsuno T., Abe S., Sato N. IL-12 and IL-18 are increased and stimulate IFN-gamma production in sarcoid lungs. J. Immunol., 2001, Vol. 166, no. 1, pp. 642-649.; Tartar D.M., VanMorlan A.M., Wan X., Guloglu F.B., Jain R., Haymaker C.L., Ellis J.S., Hoeman C.M., Cascio J.A., Dhakal M., Oukka M., Zaghouani H. FoxP3+RORgammat+ T helper intermediates display suppressive function against autoimmune diabetes. J. Immunol. (Baltimore, Md. : 1950), 2010, Vol. 184, no. 7, pp. 3377-3385.; Valencia X., Stephens G., Goldbach-Mansky R., Wilson M., Shevach E.M., Lipsky P.E. TNF downmodulates the function of human CD4+CD25hi T-regulatory cells. Blood, 2006, Vol. 108, no. 1, pp. 253-261.; Valeyre D., Brauner M., Bernaudin J.F., Carbonnelle E., Duchemann B., Rotenberg C., Berger I., Martin A., Nunes H., Naccache J.M., Jeny F. Differential diagnosis of pulmonary sarcoidosis: a review. Front. Med. (Lausanne), 2023, Vol. 10, 1150751. doi:10.3389/fmed.2023.1150751.; Wang J., Zhao X., Wan Y.Y. Intricacies of TGF-β signaling in Treg and Th17 cell biology. Cell. Mol. Immunol., 2023. Vol. 20, no. 9, pp. 1002-1022.; Weeratunga P., Moller D.R., Ho L.P. Immune mechanisms in fibrotic pulmonary sarcoidosis. Eur. Respir. Rev., 2022, Vol. 31, no. 166, 220178. doi:10.1183/16000617.0178-2022.; Zhang H., Costabel U., Dai H. The role of diverse immune cells in sarcoidosis. Front. Immunol., 2021, Vol. 12, 788502. doi:10.3389/fimmu.2021.788502.; https://www.mimmun.ru/mimmun/article/view/3046

الاتاحة: https://www.mimmun.ru/mimmun/article/view/3046
https://doi.org/10.15789/1563-0625-DOT-16797

المؤلفون: М. М. Илькович, А. Л. Акопов

المصدر: PULMONOLOGIYA; Том 33, № 1 (2023); 132-133 ; Пульмонология; Том 33, № 1 (2023); 132-133 ; 2541-9617 ; 0869-0189

مصطلحات موضوعية: Путова Н. В

وصف الملف: application/pdf

Relation: https://journal.pulmonology.ru/pulm/article/view/4264/3504; https://journal.pulmonology.ru/pulm/article/view/4264

الاتاحة: https://journal.pulmonology.ru/pulm/article/view/4264

المؤلفون: N. M. Lazareva, I. V. Kudryavtsev, O. P. Baranova, D. V. Isakov, M. K. Serebriakova, A. A. Bazhanov, N. A. Arsentieva, N. E. Liubimova, T. P. Ses’, M. M. Ilkovich, A. A. Totolian, Н. М. Лазарева, И. В. Кудрявцев, О. П. Баранова, Д. В. Исаков, М. К. Серебрякова, А. А. Бажанов, Н. А. Арсентьева, Н. Е. Любимова, Т. П. Сесь, М. М. Илькович, А. А. Тотолян

المصدر: Medical Immunology (Russia); Том 25, № 5 (2023); 1049-1058 ; Медицинская иммунология; Том 25, № 5 (2023); 1049-1058 ; 2313-741X ; 1563-0625

مصطلحات موضوعية: цитокины, CD4 + T cells, Th cell differentiation, Th17 cell subsets, flow cytometry, cytokines, Т-хелперы, дифференцировка Т-хелперов, Т-хелперы 17 типа, проточная цитометрия

وصف الملف: application/pdf

Relation: https://www.mimmun.ru/mimmun/article/view/2694/1758; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2694/10997; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2694/10998; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2694/10999; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2694/11000; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2694/11001; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2694/11002; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2694/11003; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2694/11004; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2694/11005; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2694/11021; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2694/11042; Arger N.K., Ho M.E., Allen I.E., Benn B.S., Woodruff P.G., Koth L.L. CXCL9 and CXCL10 are differentially associated with systemic organ involvement and pulmonary disease severity in sarcoidosis. Respir. Med., 2020, Vol. 161, 105822. doi:10.1016/j.rmed.2019.105822.; Bennett D., Bargagli E., Refini R.M., Rottoli P. New concepts in the pathogenesis of sarcoidosis. Expert Rev. Respir. Med., 2019, Vol. 13, no. 10, pp. 981-991.; Broos C.E., Koth L.L., van Nimwegen M., In ‘tVeen J.C.C.M., Paulissen S.M.J., van Hamburg J.P., Annema J.T., Heller-Baan R., Kleinjan A., Hoogsteden H.C., Wijsenbeek M.S., Hendriks R.W., van den Blink B., Kool M. Increased T-helper 17.1 cells in sarcoidosis mediastinal lymph nodes. Eur. Respir. J., 2018, Vol. 51, no. 3, 1701124. doi:10.1183/13993003.01124-2017.; Facco M., Cabrelle A., Teramo A., Olivieri V., Gnoato M., Teolato S., Ave E., Gattazzo C., Fadini G.P., Calabrese F., Semenzato G., Agostini C. Sarcoidosis is a Th1/Th17 multisystem disorder. Thorax, 2011, Vol. 66, no. 2, pp. 144-150.; Georas S.N., Chapman T.J., Crouser E.D. Sarcoidosis and T-helper cells. Th1, Th17, or Th17.1? Am. J. Respir. Crit. Care Med., 2016, Vol. 193, no 11, pp. 1198-1200.; Hunninghake G.W., Costabel U., Ando M., Baughman R., Cordier J.F., du Bois R., Eklund A., Kitaichi M., Lynch J., Rizzato G., Rose C., Selroos O., Semenzato G., Sharma O.P. ATS/ERS/WASOG statement on sarcoidosis. American thoracic society/European respiratory society/world association of sarcoidosis and other granulomatous disorders. Sarcoidosis Vasc. Diffuse. Lung. Dis., 1999, Vol. 16, no. 2, pp. 149-173.; Kudryavtsev I.V., Borisov A.G., Krobinets I.I., Savchenko A.A., Serebriakova M.K., Totolian A.A. Chemokine receptors at distinct differentiation stages of T-helpers from peripheral blood. Medical Immunology (Russia), 2016, Vol. 18, no. 3, pp. 239-250. (In Russ.) doi:10.15789/1563-0625-2016-3-239-250.; Kudryavtsev I.V., Lazareva N.M., Baranova O.P., Serebriakova M.K., Ses' T.P., Ilkovich M.M., Totolian Areg A. Peripheral blood T helper cell subsets in Lofgren's and non-Lofgren's syndrome patients. Medical Immunology (Russia), 2022, Vol. 24, no. 3, pp. 573-586. (In Russ.) doi:10.15789/1563-0625-PBT-2468.; Lazareva N.M., Baranova O.P., Kudryavtsev I.V., Arsentieva N.A., Liubimova N.E., Ses' T.P., Ilkovich M.M., Totolian Areg A. Features of cytokine profile in patients with sarcoidosis. Medical Immunology (Russia), 2020, Vol. 22, no. 5, pp. 993-1002. (In Russ.). doi:10.15789/1563-0625-FOC-2064.; Lazareva N.M., Baranova O.P., Kudryavtsev I.V., Arsentieva N.A., Lyubimova N.E., Ses' T.P., Ilkovich M.M., Totolian Areg A. CXCR3 chemokine receptor ligands in sarcoidosis. Medical Immunology (Russia), 2021, Vol. 23, no. 1, pp. 73-86. (In Russ.). doi:10.15789/1563-0625-CCR-2181.; Loke W.S., Herbert C., Thomas P.S. Sarcoidosis: immunopathogenesis and immunological markers. Int. J. Chronic Dis., 2013, Vol. 2013, 928601. doi:10.1155/2013/928601.; McKee A.S., Atif S.M., Falta M.T., Fontenot A.P. Innate and adaptive immunity in noninfectious granulomatous lung disease. J. Immunol., 2022, Vol. 208, no. 8, 1835-1843.; Miedema J.R., Kaiser Y., Broos C.E., Wijsenbeek M.S., Grunewald J., Kool M. Th17-lineage cells in pulmonary sarcoidosis and Lofgren's syndrome: Friend or foe? J. Autoimmun., 2018, Vol. 87, pp. 82-96.; Patterson K.C., Chen E.S. The pathogenesis of pulmonary sarcoidosis and implications for treatment. Chest, 2018, Vol. 153, no. 6, pp. 1432-1442.; Paulissen S.M., van Hamburg J.P., Dankers W., Lubberts E. The role and modulation of CCR6+ Th17 cell populations in rheumatoid arthritis. Cytokine, 2015, Vol. 74, no. 1, pp. 43-53.; Sakthivel P., Bruder D. Mechanism of granuloma formation in sarcoidosis. Curr. Opin. Hematol., 2017, Vol. 24, no. 1, pp. 59-65.; Zhang H., Costabel U., Dai H. The Role of diverse immune cells in sarcoidosis. Front. Immunol., 2021, Vol. 12, 788502. doi:10.3389/fimmu.2021.788502.; Zhou E-R., Arce S. Key players and biomarkers of the adaptive immune system in the pathogenesis of sarcoidosis. Int. J. Mol. Sci., 2020, Vol. 21, no. 19, 7398. doi:10.3390/ijms21197398.; https://www.mimmun.ru/mimmun/article/view/2694

الاتاحة: https://www.mimmun.ru/mimmun/article/view/2694
https://doi.org/10.15789/1563-0625-SCP-2694

المؤلفون: A. G. Chuchalin, S. N. Avdeev, Z. R. Aisanov, O. P. Baranova, S. E. Borisov, N. A. Geppe, A. A. Vizel’, I. Yu. Vizel’, A. A. Zaicev, N. Y. Kravchenko, M. M. Ilkovich, O. V. Lovacheva, A. B. Malakhov, A. G. Malyavin, D. V. Petrov, V. V. Romanov, I. V. Sivokozov, M. V. Samsonova, I. P. Solovieva, I. E. Stepanyan, S. A. Terpigorev, I. E. Tyurin, L. Ya. Frantsuzevich, A. L. Chernyaev, E. I. Shmelev, N. M. Shmeleva, А. Г. Чучалин, С. Н. Авдеев, З. Р. Айсанов, О. П. Баранова, С. Е. Борисов, Н. А. Геппе, А. А. Визель, И. Ю. Визель, А. А. Зайцев, Н. Ю. Кравченко, М. М. Илькович, О. В. Ловачева, А. Б. Малахов, A. Г. Малявин, Д. В. Петров, В. В. Романов, И. В. Сивокозов, М. В. Самсонова, И. П. Соловьева, И. Э. Степанян, С. А. Терпигорев, И. Е. Тюрин, Л. Я. Французевич, А. Л. Черняев, Е. И. Шмелев, Н. М. Шмелева

المصدر: PULMONOLOGIYA; Том 32, № 6 (2022); 806-833 ; Пульмонология; Том 32, № 6 (2022); 806-833 ; 2541-9617 ; 0869-0189

مصطلحات موضوعية: лечение, diagnosis, clinical manifestations, treatment, диагностика, клинические проявления

وصف الملف: application/pdf

Relation: https://journal.pulmonology.ru/pulm/article/view/4155/3472; https://journal.pulmonology.ru/pulm/article/downloadSuppFile/4155/1566; Визель А.А., ред. Саркоидоз. М.: Атмосфера; 2010.; ATS/ERS/WASOG statement on sarcoidosis. Sarcoidosis statement committee. American Thoracic Society. European Respiratory Society. World Association for Sarcoidosis and Other Granulomatous Disorders. Eur. Respir. J. 1999; 14 (4): 735–737. DOI:10.1034/j.1399-3003.1999.14d02.x.; Landi C., Carleo A., Cillis G., Rottoli P. Sarcoidosis: proteomics and new perspectives for improving personalized medicine. Expert Rev. Proteomics. 2018; 15 (10): 829–835. DOI:10.1080/14789450.2018.1528148.; Besnard V., Calender A., Bouvry D. et al. G908R NOD2 variant in a family with sarcoidosis. Respir. Res. 2018; 19 (1): 44. DOI:10.1186/s12931-018-0748-5.; Хоменко А.Г., Швайгер О., ред. Саркоидоз. М.: Медицина; 1982.; Zhao M.M., Du S.S., Li Q.H. et al. High throughput 16SrRNA gene sequencing reveals the correlation between Propionibacterium acnes and sarcoidosis. Respir. Res. 2017; 18 (1): 28. DOI:10.1186/s12931-017-0515-z.; van Dee L., Stehouwer M., van Bemmel T. Systemic sarcoidosis associated with exposure to Borrelia burgdorferi in a 21-year-old man. Eur. J. Case Rep. Intern. Med. 2018; 5 (10): 000942. DOI:10.12890/2018_000942.; Esteves T., Aparicio G., Garcia-Patos V. Is there any association between sarcoidosis and infectious agents? a systematic review and meta-analysis. BMC Pulm. Med. 2016; 16 (1): 165. DOI:10.1186/s12890-016-0332.; García Ródenas M.D.M., Gayá García-Manso I., García Sevila R. Sarcoidosis associated with Interferon beta treatment. Med. Clin. (Barc). 2019; 153 (5): e21–22. DOI:10.1016/j.medcli.2018.11.021.; Визель А.А., Визель И.Ю. Саркоидоз и интерфероны: звенья патогенеза и ятрогения. Практическая пульмонология. 2017; (1): 46–50. Доступно на: https://atmosphere-ph.ru/modules/Magazines/articles/pulmo/pp_1_2017_46.pdf; Bargagli E., Prasse A. Sarcoidosis: a review for the internist. Intern. Emerg. Med. 2018; 13 (3): 325–331. DOI:10.1007/s11739-017-1778-6.; Baughman R.P., Culver D.A., Judson M.A. A concise review of pulmonary sarcoidosis. Am. J. Respir. Crit. Care Med. 2011; 183 (5): 573–581. DOI:10.1164/rccm.201006-0865ci.; Patterson K.C., Chen E.S. The pathogenesis of pulmonary sarcoidosis and implications for treatment. Chest. 2018; 153 (6): 1432–1442. DOI:10.1016/j.chest.2017.11.030.; Hu Y., Yibrehu B., Zabini D., Kuebler W.M. Animal models of sarcoidosis. Cell Tissue Res. 2017; 367 (3): 651–661. DOI:10.1007/s00441-016-2526-3.; Dubaniewicz A. [“Danger theory”as a common mechanism of sarcoidosis induction by infectious and non-infectious factors – a role of environmental factors and autoimmunity]. Pol. Merkur. Lekarski. 2018; 44 (261): 97–100. Available at: https://www.researchgate.net/publication/324130127_Danger_theory_as_a_common_mechanism_of_sarcoidosis_induction_by_infectious_and_non-infectious_factors_-_a_role_of_genetics_factors; Jouni H., Chareonthaitawee P. Unraveling inflammation and oxidative stress in cardiac sarcoidosis. Circ. Cardiovasc. Imaging. 2017; 10 (12): e007287. DOI:10.1161/CIRCIMAGING.117.007287.; Ruža I., Lucāne Z. Serum and urinary calcium level in Latvian patients with sarcoidosis. Reumatologia. 2018; 56 (6): 377–381. DOI:10.5114/reum.2018.80715.; Suzuki T., Tsushima K., Kawata N. et al. Estimation using the impulse oscillation system in patients with pulmonary sarcoidosis. Sarcoidosis Vasc. Diffuse Lung Dis. 2015; 32 (2): 144–150. Available at: https://www.researchgate.net/publication/280876634_Estimation_Using_The_Impulse_Oscillation_System_In_Patients_With_Pulmonary_Sarcoidosis; Евфимьевский В.П., Борисов С.Е., Богородская Е.М. Нарушения дыхательной функции при гранулематозах и распространенных поражениях иной природы: пособие для врачей. М.; 1998.; Van Schalkwyk E.M., Bezuidenhout J., Wyser C.P. et al. Comparison of bronchoalveolar lavage, open lung biopsy and lung function in sarcoidosis. Eur. Resp. J. 1997; 10 (Suppl. 25): 206s. Available at: https://eurekamag.com/research/030/633/030633831.php; Ungprasert P., Matteson E.L. Neurosarcoidosis. Rheum. Dis. Clin. North Am. 2017; 43 (4): 593–606. DOI:10.1016/j.rdc.2017.06.008.; Duong H., Bonham C.A. Sarcoidosis-associated pulmonary hypertension: pathophysiology, diagnosis, and treatment. Clin. Pulm. Med. 2018; 25 (2): 52–60. DOI:10.1097/CPM.0000000000000252.; Русаков Н.В., Мухин Н.А, Брико Н.И. и др. Особенности распространения саркоидоза в условиях Москвы. Гигиена и санитария. 2012; (4): 16–18. Доступно на: https://cyberleninka.ru/article/n/osobennosti-rasprostraneniya-sarkoidoza-v-usloviyah-moskvy?ysclid=l-93wqbcyxo307456749; Баранова О.П., Рефицкая Н.В., Степаненко Т.А. и др. Эпидемиология саркоидоза органов дыхания в Санкт-Петербурге (1998–2008). В кн.: Чучалин А.Г., ред. XIX Национальный Конгресс по болезням органов дыхания: cборник трудов. М.: ДизайнПресс; 2009: 216–217.; Петров Д.В., Овсянников Н.В., Коненко А.Ю., и др. Результаты внедрения «Порядка оказания медицинской помощи больным саркоидозом» в городе Омске. Вестник современной клинической медицины. 2013; 6 (2): 42–46. Доступно на: https://cyberleninka.ru/article/n/rezultaty-vnedreniya-poryadka-okazaniya-meditsinskoy-pomoschi-bolnym-sarkoidozom-v-gorode-omske/viewer; Визель И.Ю., Визель А.А. Характеристика регистра больных саркоидозом в Республике Татарстан. Вестник современной клинической медицины. 2015; 8 (5): 18–26. Доступно на: http://vskmjournal.org/images/Files/Issues_Archive/2015/Issue_5/VSKM_2015_N_5_p18-26.pdf; Крюков Е.В., Антипушина Д.Н., Зайцев А.А. Саркоидоз – актуальная проблема различных силовых ведомств. Вестник Российской военно-медицинской академии. 2016; 56 (4): 224–227.; Baughman R.P., Field S., Costabel U. et al. Sarcoidosis in America. Analysis based on health care use. Ann. Am. Thorac. Soc. 2016; 13 (8): 1244–1252. DOI:10.1513/annalsats.201511-760oc.; Thomeer M., Demedts M., Vandeurzen K. et al. Registration of interstitial lung diseases by 20 centres of respiratory medicine in Flanders. Acta Clin. Belg. 2001; 56 (3): 163–172. DOI:10.1179/acb.2001.026.; Morimoto T., Azuma A., Abe S. et al. Epidemiology of sarcoidosis in Japan. Eur. Respir. J. 2008; 31 (2): 372–379. DOI:10.1183/09031936.00075307.; Hoffman A.L., Milman N., Byg K.E. Childhood sarcoidosis in Denmark 1979–1994: incidence, clinical features and laboratory results at presentation in 48 children. Acta Paediatr. 2004; 93 (1): 30–36. DOI:10.1111/j.1651-2227.2004.tb00670.x.; Terwiel M., van Moorsel C.H.M. Clinical epidemiology of familial sarcoidosis: a systematic literature review. Respir. Med. 2019; 149: 36–41. DOI:10.1016/j.rmed.2018.11.022.; Визель И.Ю., Шмелев Е.И., Визель А.А., Ганибаева Г.С. Сравнение вновь выявленных больных саркоидозом молодого и старшего возраста. Русский медицинский журнал. 2018; 10 (1): 16–20. Доступно на: https://www.rusmedreview.com/articles/bolezni_dykhatelnykh_putey/Sravnenie_vnovy_vyyavlennyh_bolynyh_sarkoidozom_molodogo_istarshego_vozrasta/; Терпигорев С.А., Эль Зейн Б.А., Верещагина В.М., Палеев Н.Р. Саркоидоз и проблемы его классификации. Вестник РАМН. 2012; (5): 30–37. Доступно на: https://cyberleninka.ru/article/n/sarkoidoz-i-problemy-ego-klassifikatsii/viewer; Bahmer T., Watz H., Develaska M. et al. Physical activity and fatigue in patients with sarcoidosis. Respiration. 2018; 95 (1): 18–26. DOI:10.1159/000481827.; Илькович М.М., Баранова О.П. Саркоидоз органов дыхания. В кн.: Илькович М.М., ред. Интерстициальные и орфанные заболевания легких. М.: ГЭОТАР-Медиа; 2019: 163–234.; Рабухин А.Е., Доброхотова М.Н., Тонитрова Н.С. Саркоидоз. М., Медицина; 1975.; Wanat K.A., Rosenbach M. Cutaneous sarcoidosis. Clin. Chest Med. 2015; 36 (4): 685–702. DOI:10.1016/j.ccm.2015.08.010.; Matsou A., Tsaousis K.T. Management of chronic ocular sarcoidosis: challenges and solutions. Clin. Ophthalmol. 2018; 12: 519–532. DOI:10.2147/OPTH.S128949.; Judson M.A. The clinical features of sarcoidosis: a comprehensive review. Clin. Rev. Allergy Immunol. 2015; 49 (1): 63–78. DOI:10.1007/s12016-014-8450-y.; Madaule S., Lauque D., Sailler L. et al. [Splenomegaly in sarcoidosis: clinical features and outcome. Analysis of 17 cases]. Rev. Med. Interne. 2004; 25 (5): 348–356. DOI:10.1016/j.revmed.2003.11.007 (in French).; Löffler C., Bergner R. [Sarcoidosis: renal manifestations]. Z. Rheumatol. 2017; 76 (5): 398–407. DOI:10.1007/s00393-017-0301-9 (in German).; Bechman K., Christidis D., Walsh S. et al. A review of the musculo-skeletal manifestations of sarcoidosis. Rheumatology (Oxford). 2018; 57 (5): 777–783. DOI:10.1093/rheumatology/kex317.; Chapman M.N., Fujita A., Sung E.K. et al. Sarcoidosis in the head and neck: an illustrative review of clinical presentations and imaging findings. AJR Am. J. Roentgenol. 2017; 208 (1): 66–75. DOI:10.2214/AJR.16.16058.; Иванова Д.А., Борисов С.Е., Недоступ А.В., Паша С. Поражение сердца при саркоидозе: диагностика латентных и клинически проявляющихся форм. Врач. 2008; (10): 28–33. Доступно на: https://www.elibrary.ru/download/elibrary_12924028_48123605.pdf; Dubrey S., Sharma R., Underwood R. et al. Sarcoidosis of the cardio-pulmonary systems. Clin. Med. (Lond.). 2016; 16 (1): 34–41. DOI:10.7861/clinmedicine.16-1-34.; Суслина З.А., Кистенёв Б.А., Максимова М.Ю., Моргунов В.А. Нейросаркоидоз. М.: МЕДпресс-информ; 2009.; Ibitoye R.T., Wilkins A., Scolding N.J. Neurosarcoidosis: a clinical approach to diagnosis and management. J. Neurol. 2017; 264 (5): 1023–1028. DOI:10.1007/s00415-016-8336-4.; Stern B.J., Royal W. 3rd, Gelfand J.M. et al. Definition and consensus diagnostic criteria for neurosarcoidosis: from the neurosarcoidosis Consortium Consensus Group. JAMA Neurol. 2018; 75 (12): 1546–1553. DOI:10.1001/jamaneurol.2018.2295.; Block N.L., Kava B.R. Genitourinary sarcoidosis: an essential review for the practicing clinician. Indian J. Urol. 2017; 33 (1): 6–12. DOI:10.4103/0970-1591.195724.; Ghrenassia E., Mekinian A., Chapelon-Albric C. et al. Digestive-tract sarcoidosis: French nationwide case-control study of 25 cases. Medicine (Baltimore). 2016; 95 (29): e4279. DOI:10.1097/md.0000000000004279.; Sahu P., Sharma S., Sharma N. et al. Unusual clinical presentations in early-onset childhood sarcoidosis: a correlation or coincidence? J. Clin. Diagn. Res. 2017; 11 (8): WD01–03. DOI:10.7860/JCDR/2017/27841.10389.; Fretzayas A., Moustaki M., Vougiouka O. The puzzling clinical spectrum and course of juvenile sarcoidosis. World J. Pediatr. 2011; 7 (2): 103–110. DOI:10.1007/s12519-011-0261-0.; Николаев А.В. Сравнительная оценка показателей неспецифического, клеточного и гуморального иммунитета у больных туберкулезом и саркоидозом легких. Вестник Новгородского государственного университета. 2019; 115 (3): 36–41. DOI:10.34680/2076-8052.2019.3(115).36-41; Hoffmann A. L., Milman N., Byg K. E. Childhood sarcoidosis in Denmark 1979–1994: incidence, clinical features and laboratory results at presentation in 48 children. Acta Paediatr. 2004; 93 (1): 30–36. DOI:10.1080/08035250310007213.; Kempisty A., Białas-Chromiec B., Borkowska D., Kuś J. Interferon gamma release assays based on M. tuberculosis-specific antigens in sarcoidosis patients. Pneumonol. Alergol. Pol. 2015; 83 (2): 126–134. DOI:10.5603/PiAP.2015.0020.; Gupta D., Kumar S., Aggarwal A.N. et al. Interferon gamma release assay (QuantiFERON-TB Gold in Tube) in patients of sarcoidosis from a population with high prevalence of tuberculosis infection. Sarcoidosis Vasc. Diffuse Lung Dis. 2011; 28 (2): 95–101. Available at: https://www.researchgate.net/publication/51834535_Interferon_gamma_release_assay_QuantiFERON-TB_Gold_In_Tube_in_patients_of_sarcoidosis_from_a_population_with_high_prevalence_of_tuberculosis_infection; Nosal A., Schleissner L.A., Mishkin F.S., Lieberman J. Angiotensin-I-converting enzyme and gallium scan in noninvasive evaluation of sarcoidosis. Ann. Intern. Med. 1979; 90 (3): 328–331. DOI:10.7326/0003-4819-90-3-328.; Baughman R.P., Shipley R., Eisentrout C.E. Predictive value of gallium scan, angiotensin-converting enzyme level, and bronchoalveolar lavage in two-year follow-up of pulmonary sarcoidosis. Lung. 1987; 165 (6): 371–377. DOI:10.1007/bf02714452.; Abe S., Munakata M., Nishimura M. et al. Gallium-67 scintigraphy, bronchoalveolar lavage, and pathologic changes in patients with pulmonary sarcoidosis. Chest. 1984; 85 (5): 650–655. DOI:10.1378/chest.85.5.650.; Okayama K., Kurata C., Tawarahara K. et al. Diagnostic and prognostic value of myocardial scintigraphy with thallium-201 and gallium-67 in cardiac sarcoidosis. Chest. 1995; 107 (2): 330–334. DOI:10.1378/chest.107.2.330.; Bekerman C., Szidon J. P., Pinsky S. The role of gallium-67 in the clinical evaluation of sarcoidosis. Semin. Roentgenol. 1985; 20 (4): 400–409. DOI:10.1016/0037-198x(85)90047-1.; Jerusalem G., Beguin Y., Fassotte M.F. et al. Whole-body positron emission tomography using18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin’s disease and non-Hodgkin’s lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood. 1999; 94 (2): 429–433. Available at: https://www.researchgate.net/publication/12077850_Whole-body_positron_emission_tomography_using_18F-fluorodeoxyglucose_compared_to_standard_procedures_for_staging_patients_with_Hodgkins_disease; Ozer O., Eskazan A.E., Ar M.C. et al. Sarcoidosis mimicking lymphoma on positron emission tomography-computed tomography in two patients treated for lymphoma: two case reports. J. Med. Case Rep. 2009; 3: 7306. DOI:10.4076/1752-1947-3-7306.; Dziedzic D.A., Peryt A., Orlowski T. The role of EBUS-TBNA and standard bronchoscopic modalities in the diagnosis of sarcoidosis. Clin. Respir. J. 2017; 11 (1): 58–63. DOI:10.1111/crj.12304.; Millward K., Fiddler C.A., Thillai M. Update on sarcoidosis guidelines. Curr. Opin. Pulm. Med. 2021; 27 (5): 484–489. DOI:10.1097/MCP.0000000000000807.; Demir O.F., Onal O. Is mediastinoscopy an effective diagnostic method in mediastinal area evaluation in pediatric patients? Asian. J. Surg. 2020; 43 (6): 690–695. DOI:10.1016/j.asjsur.2019.09.012.; Yoon H.Y., Kim H.M., Kim Y.J., Song J.W. Prevalence and incidence of sarcoidosis in Korea: a nationwide population-based study. Respir. Res. 2018; 19 (1): 158. DOI:10.1186/s12931-018-0871-3.; Verleden S.E., Vanstapel A., De Sadeleer L. et al. Distinct airway involvement in subtypes of end-stage fibrotic pulmonary sarcoidosis. Chest. 2021; 160 (2): 562–571. DOI:10.1016/j.chest.2021.01.003.; Khan T., Selvakumar D., Trivedi S. et al. The value of endomyocardial biopsy in diagnosis and guiding therapy. Pathology. 2017; 49 (7): 750–756. DOI:10.1016/j.pathol.2017.08.004.; Zhang C., Chan K.M., Schmidt L.A., Myers J.L. Histopathology of explanted lungs from patients with a diagnosis of pulmonary sarcoidosis. Chest. 2016; 149 (2): 499–507. DOI:10.1378/chest.15-0615.; Buxbaum J., Papademetriou M., Klipfel N. et al. Biliary sarcoidosis: early diagnosis minimizes the need for surgery. Am. J. Respir. Crit. Care Med. 2013; 187 (5): 556–559. DOI:10.1164/ajrccm.187.5.556.; Siavelis H.A., Herrmann M.E., Aranha G.V. et al. Sarcoidosis and the pancreas. Surgery. 1999; 125 (4): 456–461. DOI:10.1016/S0039-6060(99)70014-0.; Manchanda A., Patel S., Jiang J.J., Babu A.R. Thyroid: an unusual hideout for sarcoidosis. Endocr. Pract. 2013; 19 (2): e40–43. DOI:10.4158/EP12131.CR.; James D.G., Jones Williams W., eds. Sarcoidosis and other granulomatous disorders. Philadelphia: Saunders; 1985: 163–166. DOI:10.1002/PPUL.1950010513.; Шмелев Е.И. Дифференциальная диагностика диссеминированных заболеваний легких неопухолевой природы. Русский медицинский журнал. 2001; (21): 919–922. Доступно на: https://www.rmj.ru/articles/bolezni_dykhatelnykh_putey/Differencialynaya_diagnostika_disseminirovannyh_zabolevaniy_legkih_neopuholevoy_prirody/; El Sayed F., Torbey G., Youssef H., Chababi M. Childhood sarcoidosis: diagnostic issues. Dermatol. Online J. 2013; 19 (10): 20037. DOI:10.5070/D31910020037.; Deverrière G., Flamans-Klein A., Firmin D. et al. [Early onset pediatric sarcoidosis, diagnostic problems]. Arch. Pediatr. 2012; 19 (7): 707–710. DOI:10.1016/j.arcped.2012.04.024.; Bradley B., Branley H.M., Egan J.J. et al. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax. 2008; 63: v1–58. DOI:10.1136/thx.2008.101691.; Baughman R., Drent M., Judson M. et al. Sarcoidosis treatment guidelines. Available at: https://stopsarcoidosis.org/wp-content/uploads/2013/03/FSR-Physicians-Protocol1.pdf; Balasubramanian A., Wade S.W., Adler R.A. et al. Glucocorticoid exposure and fracture risk in a cohort of US patients with selected conditions. J. Bone Miner Res. 2018; 33 (10): 1881–1888. DOI:10.1002/jbmr.3523.; James W.E., Baughman R. Treatment of sarcoidosis: grading the evidence. Expert Rev. Clin. Pharmacol. 2018; 11 (7): 677–687. DOI:10.1080/17512433.2018.1486706.; Baughman R.P., Nunes H., Sweiss N.J. et al. Established and experimental medical therapy of pulmonary sarcoidosis. Eur. Respir. J. 2013; 41 (6): 1424–1438. DOI:10.1183/09031936.00060612.; Soto-Gomez N., Peters J.I., Nambiar A.M. Diagnosis and management of sarcoidosis. Am. Fam. Physician. 2016; 93 (10): 840–850. https://www.aafp.org/pubs/afp/issues/2016/0515/p840.html; Визель А. А., Калвер Д. А., Визель И. Ю. и др. Оценка влияния альфа-токоферола на течение впервые выявленного саркоидоза легких: сравнительное исследование. Туберкулез и болезни легких. 2020; 98 (10): 33–40. DOI:10.21292/2075-1230-2020-98-10-33-40.; Костина З.И. О результатах лечения саркоидоза легких. Проблемы туберкулеза. 1977; (8): 44–50.; Diallo B.D., Diot B., Flament T. et al. [The pentoxifylline, a corticosteroid sparing in the treatment of sarcoidosis: a case report]. Rev. Pneumol. Clin. 2018; 74 (1): 48–51. DOI:10.1016/j.pneumo.2017.08.014.; Refiskaya N.V., Stepanenko T.A., Jablonskiy P.K., Baranova O.P. The use of tumor necrosis factor alpha inhibitor pentoxifylline in the treatment of patients with I and II stages of pulmonary sarcoidosis. Eur. Respir. J. 2006; 28 (Suppl. 50): E3134. Available at: https://www.ers-education.org/lr/show-details/?idP=8337; Визель А.А., Визель Е.А., Насретдинова Г.Р. и др. Оценка эффективности малых доз пентоксифиллина в сочетании с токоферола ацетатом при внутригрудном саркоидозе. Пульмонология. 2005; (1): 24–28. DOI:10.18093/0869-0189-2005-0-1-24-28.; Crommelin H.A., Vorselaars A.D., van Moorsel C.H. et al. Anti-TNF therapeutics for the treatment of sarcoidosis. Immunotherapy. 2014; 6 (10): 1127–1143. DOI:10.2217/imt.14.65.; О совершенствовании санаторно-курортной и реабилитационной помощи больным туберкулезом. Приказ Минздравмедпрома РФ № 291 от 19.07.96 Доступно на: https://tkrfkod.ru/zakonodatelstvo/prikaz-minzdravmedproma-rf-ot-19071996-n-291/; Визель А.А., Гурылева М.Э. Саркоидоз у детей. Педиатрия. Журнал имени Г.Н.Сперанского. 2004; 83 (2): 62–66. Доступно на: https://pediatriajournal.ru/files/upload/mags/263/2004_2_1177.pdf; Paramothayan N., Lasserson T., Jones P. Corticosteroids for pulmonary sarcoidosis. Cochrane Database Syst. Rev. 2005; (2): CD001114. DOI:10.1002/14651858.cd001114.pub2.; ГРЛС. Преднизолон: регистрационное удостоверение. https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=5bb36449-e307-43d1-ad5a-7171d992c66a&t=; Milman N., Hoffmann A. L., Byg K. E. Sarcoidosis in children. Epidemiology in Danes, clinical features, diagnosis, treatment and prognosis. Acta Paediatrica.1998; 87 (8): 871–878. DOI:10.1080/080352598750013662.; Adami G., Saag K.G. Glucocorticoid-induced osteoporosis: 2019 concise clinical review. Osteoporos Int. 2019; 30 (6): 1145–1156. DOI:10.1007/s00198-019-04906-x.; Scherholz M.L., Schlesinger N., Androulakis I.P. Chronopharmacology of glucocorticoids. Adv. Drug Deliv. Rev. 2019. 151–152; 245–261. DOI:10.1016/j.addr.2019.02.004.; Dinsen S., Baslund B., Klose M. et al. Why glucocorticoid withdrawal may sometimes be as dangerous as the treatment itself. Eur. J. Intern. Med. 2013; 24 (8): 714–720. DOI:10.1016/j.ejim.2013.05.014.; Coker R. K. Guidelines for the use of corticosteroids in the treatment of pulmonary sarcoidosis. Drugs. 2007; 67 (8): 1139–1147. DOI:10.2165/00003495-200767080-00004.; Herlow L.B., Rasmussen N. [Laryngeal sarcoidosis in 13 year-old teenager]. Ugeskr. Laeger. 2010; 172 (45): 3116–3117. Available at: https://ugeskriftet.dk/files/scientific_article_files/2014-04//artikel_8769.pdf (in Danish).; ГРЛС. Метотрексат: регистрационное удостоверение. Доступно на: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=43da4be2-b2bc-4eaa-8031-aae6250bf870&t=; Cremers J.P., Drent M., Bast A. et al. Multinational evidence-based World Association of Sarcoidosis and Other Granulomatous Disorders recommendations for the use of methotrexate in sarcoidosis: integrating systematic literature research and expert opinion of sarcoidologists worldwide. Curr. Opin. Pulm. Med. 2013; 19 (5): 545–561. DOI:10.1097/mcp.0b013e3283642a7a.; Гаврисюк В., Меренкова Е., Гуменюк Г. и др. Эффективность и безопасность монотерапии метотрексатом у пациентов с саркоидозом легких. Georgian Med. News. 2018; (283): 34–38. Доступно на: https://geomednews.com/s/480918712df344a4a77508d4cd7815ab/files/uploaded/V283_N10_October_2018.pdf?; Baughman R.P., Winget D.B., Lower E.E. Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial. Sarcoidosis Vasc. Diffuse Lung Dis. 2000; 17 (1): 60–66. Available at: https://read.qxmd.com/read/10746262/methotrexate-is-steroid-sparing-in-acute-sarcoidosis-results-of-a-double-blind-randomized-trial; Визель А.А., Визель И.Ю. Применение метотрексата при саркоидозе (по данным контролируемого проспективного исследования). Клиническая медицина. 2015; 93 (1): 41–46. Доступно на: https://cyberleninka.ru/article/n/primenenie-metotreksata-pri-sarkoidoze-po-dannym-kontroliruemogo-prospektivnogo-issledovaniya/viewer; Gedalia A., Molina J.F., Ellis G.S. Jr. et al. Low-dose methotrexate therapy for childhood sarcoidosis. J. Pediatr. 1997; 130 (1): 25–29. DOI:10.1016/s0022-3476(97)70306-8.; Gedalia A., Khan T.A., Shetty A.K. et al. Childhood sarcoidosis: Louisiana experience. Clin. Rheumatol. 2016; 35 (7): 1879–1884. DOI:10.1007/s10067-015-2870-9.; Birnie D., Beanlands R.S.B., Nery P. et al. Cardiac sarcoidosis multi-center randomized controlled trial (CHASM CS-RCT). Am. Heart J. 2020; 220: 246–252. DOI:10.1016/j.ahj.2019.10.003.; Ning N., Guo H.H., Iagaru A. et al. Serial cardiac FDG-PET for the diagnosis and therapeutic guidance of patients with cardiac sarcoidosis. J. Card. Fail. 2019; 25 (4): 307–311. DOI:10.1016/j.cardfail.2019.02.018.; Soriano F. G., Caramelli P., Nitrini R., Rocha A.S. Neurosarcoidosis: therapeutic success with methotrexate. Postgrad. Med. J. 1990; 66 (772): 142–143. DOI:10.1136/pgmj.66.772.142.; Judson M. A. Sarcoidosis: clinical presentation, diagnosis, and approach to treatment. Am. J. Med. Sci. 2008; 335 (1): 26–33. DOI:10.1097/maj.0b013e31815d8276.; Vorselaars A.D., Cremers J.P., Grutters J.C., Drent M. Cytotoxic agents in sarcoidosis: which one should we choose? Curr. Opin. Pulm. Med. 2014; 20 (5): 479–487. DOI:10.1097/mcp.0000000000000078.; Ballul T., Borie R., Crestani B. et al. Treatment of cardiac sarcoidosis: a comparative study of steroids and steroids plus immunosuppressive drugs. Int. J. Cardiol. 2019; 276: 208–211. DOI:10.1016/j.ijcard.2018.11.131.; Lewis S.J., Ainslie G.M., Bateman E.D. Efficacy of azathioprine as second-line treatment in pulmonary sarcoidosis. Sarcoidosis Vasc. Diffuse Lung Dis. 1999; 16 (1): 87–92. Available at: https://www.semanticscholar.org/paper/Efficacy-of-azathioprine-as-second-line-treatment-Lewis-Ainslie/f8f6fe3938be432c3d49af53d4d8fcacac308453; Beegle S.H., Barba K., Gobunsuy R., Judson M.A. Current and emerging pharmacological treatments for sarcoidosis: a review. Drug Des. Devel. Ther. 2013; 7: 325–328. DOI:10.2147/dddt.s31064.; ГРЛС. Азатиоприн: регистрационное удостоверение Доступно на: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=186056b6-254d-44c1-a1c8-aac7f595a198&t=; El Jammal T., Jamilloux Y., Gerfaud-Valentin M. et al. Refractory sarcoidosis: a review. Ther. Clin. Risk. Manag. 2020; 16: 323–345. DOI:10.2147/TCRM.S192922.; Baughman R.P., Lower E.E. Leflunomide for chronic sarcoidosis. Sarcoidosis Vasc. Diffuse Lung Dis. 2004; 21 (1): 43–48. DOI:10.1007/s11083-004-5178-y.; Raj R., Nugent K. Leflunomide-induced interstitial lung disease (a systematic review). Sarcoidosis Vasc. Diffuse Lung Dis. 2013; 30 (3): 167–176. Available at: https://www.researchgate.net/publication/258957656_Leflunomide-induced_interstitial_lung_disease_a_systematic_review; Bohelay G., Bouaziz J.D., Nunes H. et al. Striking leflunomide efficacy against refractory cutaneous sarcoidosis. J. Am. Acad. Dermatol. 2014; 70 (5): e111–113. DOI:10.1016/j.jaad.2013.10.048.; Sahoo D.H., Bandyopadhyay D., Xu M. et al. Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis. Eur. Respir. J. 2011; 38 (5): 1145–1150. DOI:10.1183/09031936.00195010.; ГРЛС. Арресто: регистрационное удостоверение Доступно на: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=46c1c8dd-0c2e-48b0-bf3e-be5a206a1238&t=; Hamzeh N., Voelker A., Forssen A. et al. Efficacy of mycophenolate mofetil in sarcoidosis. Respir. Med. 2014; 108 (11): 1663–1669. DOI:10.1016/j.rmed.2014.09.013.; Мухин Н.А., ред. Саркоидоз: клинические рекомендации. М.: ИМА-ПРЕСС; 2009.; Kikuchi N., Nunoda S., Serizawa N. et al. Combination therapy with corticosteroid and mycophenolate mofetil in a case of refractory cardiac sarcoidosis. J. Cardiol. Cases. 2016; 13 (4): 125–128. DOI:10.1016/j.jccase.2015.12.008.; ГРЛС. Фломирен: регистрационное удостоверение. Доступно на: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=9fd35729-ab22-4b2c-a80d-41619164b8b2&t=; Moudgil A., Przygodzki R. M., Kher K. K. Successful steroid-sparing treatment of renal limited sarcoidosis with mycophenolate mofetil. Pediatr. Nephrol. 2006; 21 (2): 281–285. DOI:10.1007/s00467-005-2086-3.; ГРЛС. Эндоксан: регистрационное удостоверение. Доступно на: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=cc8c311d-6bae-4a30-b1d2-f4e74e5f3644&t; Rabinowitz M.P., Murchison A.P. Orbital sarcoidosis treated with hydroxychloroquine. Orbit. 2011; 30 (1): 13–15. DOI:10.3109/01676830.2010.524268.; Kiedrowicz M., Kacalak-Rzepka A., Bielecka-Grzela S., Maleszka R. [Antimalarial drugs in contemporary dermatologic therapy]. Ann. Acad. Med. Stetin. 2011; 57 (1): 38–44. Available at: https://www.researchgate.net/publication/224975968_Antimalarial_drugs_in_contemporary_dermatologic_therapy; ГРЛС. Плаквенил: регистрационное удостоверение. Доступно на: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=92eff6a5-c78c-4d28-910b-cdcc78986307&t=; Baltzan M., Mehta S., Kirkham T.H., Cosio M.G. Randomized trial of prolonged chloroquine therapy in advanced pulmonary sarcoidosis. Am. J. Respir. Crit. Care Med. 1999; 160 (1): 192–197. DOI:10.1164/ajrccm.160.1.9809024.; Zabel P., Entzian P., Dalhoff K., Schlaak M. Pentoxifylline in treatment of sarcoidosis. Am. J. Respir. Crit. Care Med. 1997; 155 (5): 1665–1669. DOI:10.1164/ajrccm.155.5.9154873.; Park M.K., Fontana Jr., Babaali H. et al. Steroid-sparing effects of pentoxifylline in pulmonary sarcoidosis. Sarcoidosis Vasc. Diffuse Lung Dis. 2009; 26 (2): 121–131. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2946799/; Popova E.N., Bolevich S.B., Fomin V.V. et al. Pulmonary hypertension associated with sarcoidosis and experience of treatment with pentoxifylline (Vasonite). Eur. Respir. J. 2006; 28 (Suppl. 50): 2491. Available at: https://www.ers-education.org/lr/show-details/?idP=7643; Бородина Г.Л. Антицитокиновая терапия пентоксифиллином в виде монотерапии и в сочетании с глюкокортикостероидами при саркоидозе органов дыхания. Туберкулз и болезни легких. 2013; (8): 15–20. Доступно на: https://www.elibrary.ru/download/elibrary_20658497_99153726.pdf; Костина З.И., Браженко Н.А., Насорина Р.Н. Отдаленные результаты наблюдения за леченными больными саркоидозом органов дыхания. Проблемы туберкулеза. 1995; (3): 34–37.; Зубович Г.Л., Абрамовская А.К., Камышников В.С. и др. Показатели гомеостаза у больных саркоидозом органов дыхания. Пульмонология. 1996; (2): 50–54. Доступно на: https://journal.pulmonology.ru/pulm/article/view/3430/2817; Drent M., Cremers J.P., Jansen T.L., Baughman R.P. Practical eminence and experiencebased recommendations for use of TNF-alpha inhibitors in sarcoidosis. Sarcoidosis Vasc. Diffuse Lung Dis. 2014; 31 (2): 91–107. Available at: https://www.wasog.org/dynamic/media/78/documents/2014_Drent_et_al_Sarcoidosis_anti-TNF.pdf; Simonini G., Taddio A., Cattalini M. et al. Prevention of flare recurrences in childhood-refractory chronic uveitis: an open-label comparative study of adalimumab versus infliximab. Arthritis Care Res. (Hoboken). 2011; 63 (4): 612–618. DOI:10.1002/acr.20404.; Orandi A.B., Eutsler E., Ferguson C. et al. Sarcoidosis presenting as granulomatous myositis in a 16-year-old adolescent. Pediatr. Rheumatol. Online J. 2016; 14 (1): 59. DOI:10.1186/s12969-016-0121-5.; Judson M.A., Baughman R.P., Costabel U. et al. Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis. Eur. Respir. J. 2014; 44 (5): 1296–1307. DOI:10.1183/09031936.00000914.; Utz J.P., Limper A.H., Kalra S. et al. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest. 2003; 124 (1): 177–185. DOI:10.1378/chest.124.1.177.; Majjad A., Bezza A., Biyi A. et al. Pulmonary sarcoidosis following etanercept treatment for ankylosing spondylitis: a case report and review of the literature. Case Rep. Rheumatol. 2018; 2018: 9867248. DOI:10.1155/2018/9867248.; Kim T.K., Kang S.H., Moon H.S. et al. Pulmonary sarcoidosis that developed during the treatment of a patient with Crohn disease by using infliximab. Ann. Coloproctol. 2017; 33 (2): 74–77. DOI:10.3393/ac.2017.33.2.74.; Инструкция по медицинскому применению лекарственного препарата Варгатеф®. Дата утверждения МЗ РФ 10.07.20. Доступно на: https://www.boehringer-ingelheim.ru/sites/ru/files/files/vargatef_pil_10-07-2020.pdf; Flaherty K.R., Wells A. U., Cottin V. et al. Nintedanib in progressive fibrosing interstitial lung diseases. N. Engl. J. Med. 2019; 381 (18): 1718–1727. DOI:10.1056/NEJMoa1908681.; Шмелёв Е.И. Саркоидоз. Пульмонология и аллергология. 2004; 13 (2): 3–10. Доступно на: https://atmosphere-ph.ru/modules/Magazines/articles/pulmo/ap_2_2004_03.pdf; Романов В.В. Экстракорпоральные методы в лечении больных саркоидозом. Проблемы туберкулеза. 2001; (3): 45–49.; Баранова О.П., Бакланова О.Э., Войнов В.А., Карчевский К.С. Применение плазмафереза в комплексном лечении больных саркоидозом легких. В кн.: Чучалин А.Г., ред. XIX Национальный Конгресс по болезням органов дыхания: cборник трудов. М.: ДизайнПресс, 2009: 215.; Смелая Т.В., Сивцевич Н.Н., Жолобов И.М. Экстракорпоральная фармакотерапия при лечении пациентов с различной нозологией. Медицинский вестник МВД. 2017; 91 (6): 44–50.; Taimeh Z., Hertz M.I., Shumway S., Pritzker M. Lung transplantation for pulmonary sarcoidosis. Twenty-five years of experience in the USA. Thorax. 2016; 71 (4): 378–379. DOI:10.1136/thorax-jnl-2015-207497.; Salamo O., Roghaee S., Schweitzer M.D. et al. White donor, younger donor and double lung transplant are associated with better survival in sarcoidosis patients. Sci. Rep. 2018; 8 (1): 6968. DOI:10.1038/s41598-018-25144-x.; Meyer K.C. Lung transplantation for pulmonary sarcoidosis. Sarcoidosis Vasc. Diffuse Lung Dis. 2019; 36 (2): 92–107. DOI:10.36141/svdld.v36i2.7163.; Rosenthal D.G., Anderson M.E., Petek B.J. et al. Invasive hemodynamics and rejection rates in patients with cardiac sarcoidosis after heart transplantation. Can. J. Cardiol. 2018; 34 (8): 978–982. DOI:10.1016/j.cjca.2018.03.021.; Sawahata M., Shijubo N., Johkoh T. et al. Progression of central-peripheral band and traction bronchiectasis clusters leading to chronic respiratory failure in a patient with fibrotic pulmonary sarcoidosis. Intern. Med. 2021; 60 (1): 111–116. DOI:10.2169/internalmedicine.4862-20.; Faverio P., De Giacomi F., Sardella L. et al. Management of acute respiratory failure in interstitial lung diseases: overview and clinical insights. BMC Pulm. Med. 2018; 18 (1): 1–13. DOI:10.1186/s12890-018-0643-3.; Авдеев С.Н. Легочная гипертензия при саркоидозе. Пульмонология. 2016; 26 (6): 725–735. DOI:10.18093/0869-0189-2016-26-6-725-735.; Parikh K.S., Dahhan T., Nicholl L. et al. Clinical features and outcomes of patients with sarcoidosis-associated pulmonary hypertension. Sci. Rep. 2019; 9 (1): 4061. DOI:10.1038/s41598-019-40030-w.; Corte T.J., Wells A.U., Nicholson A.G. et al. Pulmonary hypertension in sarcoidosis: a review. Respirology. 2011; 16 (1): 69–77. DOI:10.1111/j.1440-1843.2010.01872.x.; Бородина Г.Л. Разработка программы медицинской реабилитации пациентов с саркоидозом органов дыхания и оценка ее эффективности. Вестник современной клинической медицины. 2012; 5 (1): 11–20. Доступно на: http://vskmjournal.org/images/Files/Issues_Archive/2012/Issue_1/VSKM_2012_N_1_p11-20.pdf; Niedoszytko P. [Rehabilitation of patients with sarcoidosis]. Pol. Merkur. Lekarski. 2018; 44 (261): 150–151. Available at: https://www.researchgate.net/publication/324129986_Rehabilitation_of_patients_with_sarcoidosis; Черников А.Ю. Об эффективности медицинской реабилитации больных саркоидозом в общей лечебной сети. Здравоохранение Российской Федерации. 2008; (4): 36–39.; Черников А.Ю., Дауров Б.И. Эффективность диспансеризации больных саркоидозом в условиях общей лечебной сети. Проблемы туберкулtза и болезней лtгких. 2007; 84 (8): 3–5.; Гармаш Ю.Ю. Основные принципы наблюдения за больными саркоидозом. Российский медицинский журнал. 2009; (1): 22–23.; https://journal.pulmonology.ru/pulm/article/view/4155

الاتاحة: https://journal.pulmonology.ru/pulm/article/view/4155
https://doi.org/10.18093/0869-0189-2022-32-6-806-833

المؤلفون: S. N. Avdeev, Z. R. Aisanov, A. S. Belevskiy, M. M. Ilkovich, E. A. Kogan, Z. M. Merzhoeva, D. V. Petrov, M. V. Samsonova, S. A. Terpigorev, N. V. Trushenko, I. N. Trofimenko, I. E. Tyurin, A. L. Chernyaev, B. A. Chernyak, A. V. Chernyak, S. Yu. Chikina, A. G. Chuchalin, E. I. Shmelev, С. Н. Авдеев, З. Р. Айсанов, А. С. Белевский, М. М. Илькович, Е. А. Коган, З. М. Мержоева, Д. В. Петров, М. В. Самсонова, С. А. Терпигорев, Н. В. Трушенко, И. Н. Трофименко, И. Е. Тюрин, А. Л. Черняев, Б. А. Черняк, А. В. Черняк, С. Ю. Чикина, А. Г. Чучалин, Е. И. Шмелев

المصدر: PULMONOLOGIYA; Том 32, № 3 (2022): Спецвыпуск; 473-495 ; Пульмонология; Том 32, № 3 (2022): Спецвыпуск; 473-495 ; 2541-9617 ; 0869-0189

مصطلحات موضوعية: антифибротическая терапия, interstitial lung disease, usual interstitial pneumonia, antifibrotic therapy, интерстициальные заболевания легких, обычная интерстициальная пневмония

وصف الملف: application/pdf

Relation: https://journal.pulmonology.ru/pulm/article/view/4111/3417; Raghu G., Collard H.R., Egan J.J. et al. An official ATS/ERS/JRS/ ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am. J. Respir. Crit. Care Med. 2011; 183 (6): 788–824. DOI:10.1164/rccm.2009-040GL.; Raghu G., Rochwerg B., Zhang Y. et al. An Official ATS/ERS/ JRS/ALAT clinical practice guideline: treatment of Idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am. J. Respir. Crit. Care Med. 2015; 192 (2): e3–19. DOI:10.1164/rccm.201506-1063ST.; Travis W.D., Costabel U., Hansell D.M. et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am. J. Respir. Crit. Care Med. 2013; 188 (6): 733–748. DOI:10.1164/rccm.201308-1483ST.; Hodgson U., Pulkkinen V., Dixon M. et al. ELMOD2 is a candidate gene for familial idiopathic pulmonary fibrosis. Am. J. Hum. Genet. 2006; 79 (1): 149–154. DOI:10.1086/504639.; Allen R.J., Porte J., Braybrooke R. et al. Genetic variants associated with susceptibility to idiopathic pulmonary fibrosis in people of European ancestry: a genome-wide association study. Lancet Respir. Med. 2017; 5 (11): 869–880. DOI:10.1016/S2213-2600(17)30387-9.; Авдеев С.Н. Идиопатический фиброз легких: новая парадигма. Терапевтический архив. 2017; 89 (1): 112–122. DOI:10.17116/terarkh2017891112-122; Taskar V.S., Coultas D.B. Is idiopathic pulmonary fibrosis an environmental disease. Proc. Am. Thorac. Soc. 2006; 3 (4): 293–298. DOI:10.1513/pats.200512-131TK.; Bedard Methot D., Leblanc E., Lacasse Y. Meta-analysis of gastroesophageal reflux disease and idiopathic pulmonary fibrosis. Chest. 2019; 155 (1): 33–43. DOI:10.1016/j.chest.2018.07.038.; Garcıa-Sancho Figueroa M.C., Carrillo G., Pérez-Padilla R. et al. Risk factors for idiopathic pulmonary fibrosis in a Mexican population: a case-control study. Respir. Med. 2010; 104 (2): 305–309. DOI:10.1016/j.rmed.2009.08.013.; Oldham J.M., Kumar D., Lee C. et al. Thyroid disease is prevalent and predicts survival in patients with idiopathic pulmonary fibrosis. Chest. 2015; 148 (3): 692–700. DOI:10.1378/chest.14-2714.; Stock C.J., Sato H., Fonseca C. et al. Mucin 5B promoter polymorphism is associated with idiopathic pulmonary fibrosis but not with development of lung fibrosis in systemic sclerosis or sarcoidosis. Thorax. 2013; 68 (5): 436–441. DOI:10.1136/thoraxjnl-2012-201786.; El-Chemaly S., Ziegler S.G., Calado R.T. et al. Natural history of pulmonary fibrosis in two subjects with the same telomerase mutation. Chest. 2011; 139 (5): 1203–1209. DOI:10.1378/chest.10-2048.; Tsang A.R., Wyatt H.D., Ting N.S.Y., Beattie T.L. hTERT mutations associated with idiopathic pulmonary fibrosis affect telomerase activity, telomere length, and cell growth by distinct mechanisms. Aging Cell. 2012; 11 (3): 482–490. DOI:10.1111/j.1474-9726.2012.00810.x.; Fukuhara A., Tanino Y., Ishii T., et al. Pulmonary fibrosis in dyskeratosis congenita with TINF2 gene mutation. Eur. Respir. J. 2013; 42 (6): 1757–1759. DOI:10.1183/09031936.00149113.; Kropski J.A., Mitchell D.B., Markin C. et al. A novel dyskerin (DKC1) mutation is associated with familial interstitial pneumonia. Chest. 2014; 146 (1): e1–7. DOI:10.1378/chest.13-2224.; Alder J.K., Stanley S.E., Wagner C.L. et al. Exome sequencing identifies mutant TINF2 in a family with pulmonary fibrosis. Chest. 2015; 147 (5): 1361–1368. DOI:10.1378/chest.14-1947.; Чучалин А.Г., Авдеев С.Н., Айсанов З.Р. и др. Диагностика и лечение идиопатического легочного фиброза: Федеральные клинические рекомендации. Пульмонология. 2016; 26 (4): 399–419. DOI:10.18093/0869-0189-2016-26-4-399-419.; Raghu G., Chen S.Y., Yeh W.S. et al. Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-11. Lancet Respir. Med. 2014; 2 (7): 566–572. DOI:10.1016/S2213-2600(14)70101-8.; Raghu G., Weycker D., Edelsberg J. et al. Incidence and prevalence of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2006; 174 (7): 810–816. DOI:10.1164/rccm.200602-163OC.; Coultas D.B., Zumwalt R.E., Black W.C., Sobonya R.E. The epidemiology of interstitial lung diseases. Am. J. Respir. Crit. Care Med. 1994; 150 (4): 967–972. DOI:10.1164/ajrccm.150.4.7921471.; Nalysnyk L., Cid-Ruzafa J., Rotella P., Esser D. Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature. Eur. Respir. Rev. 2012; 21 (126): 355–361. DOI:10.1183/09059180.00002512.; Richeldi L., Rubin A.S., Avdeev S. et al. Idiopathic pulmonary fibrosis in BRIC countries: the cases of Brazil, Russia, India, and China. BMC Medicine. 2015; 13: 237. DOI:10.1186/s12916-015-0495-0.; Raghu G., Remy-Jardin M., Myers J.L. et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am. J. Respir. Crit. Care Med. 2018; 198 (5): e44–68. DOI:10.1164/rccm.201807-1255ST.; Lynch D.A., Sverzellati N., Travis W.D. et al. Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper. Lancet Respir. Med. 2018; 6 (2): 138–153. DOI:10.1016/S2213-2600(17)30433-2.; George R.B., Light R.W., Mattay M.A., Mattay R.A., eds. Chest Medicine: Essentials of Pulmonary and Critical Care Medicine. 5th edn. Philadelphia: Wolter Kluwers/Lippincott Williams & Wilkins; 2005.; Collard H.R., Ryerson C.J., Corte T.J. et al. Acute exacerbation of idiopathic pulmonary fibrosis: An international working group report. Am. J. Respir. Crit. Care Med. 2016; 194 (3): 265–275. DOI:10.1164/rccm.201604-0801CI.; Gross T.J., Hunninghake G.W. Idiopathic pulmonary fibrosis. N. Engl. J. Med. 2001; 345 (7): 517–525. DOI:10.1056/NEJMra003200.; King T.E., Tooze J.A., Schwarz M.I. et al. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am. J. Respir. Crit. Care Med. 2001; 164 (7): 1171–1181. DOI:10.1164/ajrccm.164.7.2003140.; Авдеев С.Н. Обострение идиопатического легочного фиброза. Пульмонология. 2018; 28 (4): 469–482. DOI:10.18093/0869-0189-2018-28-4-469-482.; Ambrosini V., Cancellieri A., Chilosi M. et al. Acute exacerbation of idiopathic pulmonary fibrosis: report of a series. Eur. Respir. J. 2003; 22 (5): 821–826. DOI:10.1183/09031936.03.00022703.; Kim D.S., Park J.H., Park B.K. et al. Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features. Eur. Respir. J. 2006; 27 (1): 143–150. DOI:10.1183/09031936.06.00114004.; Rajala K., Lehto J.T., Sutinen E. et al. mMRC dyspnoea scale indicates impaired quality of life and increased pain in patients with idiopathic pulmonary fibrosis. ERJ Open Res. 2017; 3 (4): 00084- 2017. DOI:10.1183/23120541.00084-2017.; Ley B., Ryerson C.J., Vittinghoff E. et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann. Intern. Med. 2012; 156 (10): 684–691. DOI:10.7326/0003-4819-156-10-201205150-00004.; Sgalla G., Walsh S.L.F., Sverzellati N. et al. “Velcro-type” crackles predict specific radiologic features of fibrotic interstitial lung disease. BMC Pulm. Med. 2018; 18 (1): 103. DOI:10.1186/s12890-018-0670-0.; Collard H.R., King T.E. Jr, Bartelson B.B. et al. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2003; 168 (5): 538–542. DOI:10.1164/rccm.200211-1311OC.; Wells A.U., Desai S.R., Rubens M.B. et al. Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am. J. Respir. Crit. Care Med. 2003; 167 (7): 962–969. DOI:10.1164/rccm.2111053.; Mathieson J.R., Mayo J.R., Staples C.A., Muller N.L. Chronic diffuse infiltrative lung disease: comparison of diagnostic accuracy of CT and chest radiography. Radiology. 1989; 171 (1): 111–116. DOI:10.1148/radiology.171.1.2928513.; Remy-Jardin M., Campistron P., Amara A. et al. Usefulness of coronal reformations in the diagnostic evaluation of infiltrative lung disease. J. Comput. Assist. Tomogr. 2003; 27 (2): 266–273. DOI:10.1097/00004728-200303000-00028.; Bankier A.A., O’Donnell C.R., Boiselle P.M. Quality initiatives. Respiratory instructions for CT examinations of the lungs: a handson guide. Radiographics. 2008; 28 (4): 919–931. DOI:10.1148/rg.284085035.; Kim M., Lee S.M., Song J.W. et al. Added value of prone CT in the assessment of honeycombing and classification of usual interstitial pneumonia pattern. Eur. J. Radiol. 2017; 91: 66–70. DOI:10.1016/j.ejrad.2017.03.018.; Gotway M.B., Lee E.S., Reddy G.P. et al. Low-dose, dynamic, expiratory thin-section CT of the lungs using a spiral CT scanner. J. Thorac. Imaging. 2000; 15 (3): 168–172. DOI:10.1097/00005382-200007000-00003.; Lynch D.A., Godwin J.D., Safrin S. et al. High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis. Am. J. Respir. Crit. Care Med. 2005; 172 (4): 488–493. DOI:10.1164/rccm.200412-1756OC.; Remy-Jardin M., Giraud F., Remy J. et al. Importance of groundglass attenuation in chronic diffuse infiltrative lung disease: pathologic-CT correlation. Radiology. 1993; 189 (3): 693–698. DOI:10.1148/radiology.189.3.8234692.; Silva C.I., Müller N.L., Lynch D.A. et al. Chronic hypersensitivity pneumonitis: differentiation from idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia by using thin-section CT. Radiology. 2008; 246 (1): 288–297. DOI:10.1148/radiol.2453061881.; Raghu G., Mageto Y.N., Lockhart D. et al. The accuracy of the clinical diagnosis of new-onset idiopathic pulmonary fibrosis and other interstitial lung disease: a prospective study. Chest. 1999; 116 (5): 1168–1174. DOI:10.1378/chest.116.5.1168.; Chung J.H., Chawla A., Peljto A.L. et al. CT scan findings of probable usual interstitial pneumonitis have a high predictive value for histologic usual interstitial pneumonitis. Chest. 2015; 147 (2): 450–459. DOI:10.1378/chest.14-0976.; Cottin V., Nunes H., Brillet P.Y. et al. Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur. Respir. J. 2005; 26 (4): 586–593. DOI:10.1183/09031936.05.00021005.; Behr J., Kreuter M., Hoeper M.M. et al. Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry. Eur. Respir. J. 2015; 46 (1): 186–196. DOI:10.1183/09031936.00217614.; Akagi T., Matsumoto T., Harada T. et al. Coexistent emphysema delays the decrease of vital capacity in idiopathic pulmonary fibrosis. Respir. Med. 2009; 103 (8): 1209–1215. DOI:10.1016/j.rmed.2009.02.001.; Enright P.L. The Six-Minute Walk Test. Respir. Care. 2003; 48 (8): 783–785. Available at: http://rc.rcjournal.com/content/48/8/783.full.pdf; Lama V.N., Flaherty K.R., Toews G.B. et al. Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. Am. J. Respir. Crit. Care Med. 2003; 168 (9): 1084–1090. DOI:10.1164/rccm.200302-219OC.; du Bois R.M., Weycker D., Albera C. et al. Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am. J. Respir. Crit. Care Med. 2011; 184 (12): 1382–1389. DOI:10.1164/rccm.201105-0840OC.; Caminati A., Bianchi A., Cassandro R. et al. Walking distance on 6-MWT is a prognostic factor in idiopathic pulmonary fibrosis. Respir. Med. 2009; 103 (1): 117–123. DOI:10.1016/j.rmed.2008.07.022.; Lederer D.J., Arcasoy S.M., Wilt J.S. et al. Six-minute-walk distance predicts waiting list survival in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2006; 174 (6): 659–664. DOI:10.1164/rccm.200604-520OC.; Dowman L., Hill C.J., Holland A.E. Pulmonary rehabilitation for interstitial lung disease. Cochrane Database Syst. Rev. 2014; (10): CD006322. DOI:10.1002/14651858.CD006322.pub3.; Mapel D.W., Samet J.M., Coultas D.B. Corticosteroids and the treatment of idiopathic pulmonary fibrosis: Past, present, and future. Chest. 1996; 110 (4): 1058–1067. DOI:10.1378/chest.110.4.1058.; Hanson D., Winterbauer R.H., Kirtland S.H., Wu R. Changes in pulmonary function test results after 1 year of therapy as predictors of survival in patients with idiopathic pulmonary fibrosis. Chest. 1995; 108 (2): 305–310. DOI:10.1378/chest.108.2.305.; Douglas W.W., Ryu J.H., Schroeder D.R. Idiopathic pulmonary fibrosis: impact of oxygen and colchicine, prednisone, or no therapy on survival. Am. J. Respir. Crit. Care Med. 2000; 161 (4, Pt 1): 1172–1178. DOI:10.1164/ajrccm.161.4.9907002.; Raghu G., Depaso W.J., Cain K. et al. Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial. Am. Rev. Respir. Dis. 1991; 144 (2): 291–296. DOI:10.1164/ajrccm/144.2.291.; Flaherty K.R., Toews G.B., Lynch J.P. et al. Steroids in idiopathic pulmonary fibrosis: a prospective assessment of adverse reactions, response to therapy, and survival. Am. J. Med. 2001; 110 (4): 278–282. DOI:10.1016/s0002-9343(00)00711-7.; Idiopathic Pulmonary Fibrosis Clinical Research Network; Martinez F.J., de Andrade J.A., Anstrom K.J. et al. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2014; 370 (22): 2093–2101. DOI:10.1056/NEJMoa1401739.; Behr J., Maier K., Degenkolb B. et al. Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis: adjunctive therapy to maintenance immunosuppression. Am. J. Respir. Crit. Care Med. 1997; 156 (6): 1897–1901. DOI:10.1164/ajrccm.156.6.9706065.; Tomioka H., Kuwata Y., Imanaka K. et al. A pilot study of aerosolized N-acetylcysteine for idiopathic pulmonary fibrosis. Respirology. 2005; 10 (4): 449–455. DOI:10.1111/j.1440-1843.2005.00725.x.; Oldham J.M., Ma S.F., Martinez F.J. et al. TOLLIP, MUC5B, and the response to N-acetylcysteine among individuals with idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2015; 192 (12): 1475–1482. DOI:10.1164/rccm.201505-1010OC.; Demedts M., Behr J., Buhl R. et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2005; 353 (21): 2229–2242. DOI:10.1056/NEJMoa042976.; Idiopathic Pulmonary Fibrosis Clinical Research Network; Raghu G., Anstrom K.J., King T.E. Jr et al. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N. Engl. J. Med. 2012; 366 (21): 1968–1977. DOI:10.1056/NEJMoa1113354.; Raghu G., Behr J., Brown K.K. et al. Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. Ann. Intern. Med. 2013; 158 (9): 641–649. DOI:10.7326/0003-4819-158-9-201305070-00003.; Noth I., Anstrom K.J., Calvert S.B. et al. A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2012; 186 (1): 88–95. DOI:10.1164/rccm.201202-0314OC.; Lee J.S., Collard H.R., Anstrom K.J. et al. Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials. Lancet Respir. Med. 2013; 1 (5): 369–376. DOI:10.1016/S2213-2600(13)70105-X.; Tran T., Suissa S. The effect of anti-acid therapy on survival in idiopathic pulmonary fibrosis: a methodological review of observational studies. Eur. Respir. J. 2018; 51 (6): 1800376. DOI:10.1183/13993003.00376-2018.; Di Martino E., Provenzani A., Vitulo P., Polidori P. Systematic review and meta-analysis of pirfenidone, nintedanib, and pamrevlumab for the treatment of idiopathic pulmonary fibrosis. Ann. Pharmacother. 2021; 55 (6): 723–731. DOI:10.1177/1060028020964451.; Lancaster L., Crestani B., Hernandez P. et al. Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials. BMJ Open Respir. Res. 2019; 6 (1): e000397. DOI:10.1136/bmjresp-2018-000397.; Skandamis A., Kani C., Markantonis S.L., Souliotis K. Systematic review and network meta-analysis of approved medicines for the treatment of idiopathic pulmonary fibrosis. J. Drug Assess. 2019; 8 (1): 55–61. DOI:10.1080/21556660.2019.1597726.; Richeldi L., Costabel U., Selman M. et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2011; 365 (12): 1079–1087. DOI:10.1056/NEJMoa1103690.; Richeldi L., du Bois R.M., Raghu G. et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2014; 370 (22): 2071–2082. DOI:10.1056/NEJMoa1402584.; Crestani B., Huggins J.T., Kaye M. et al. Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON. Lancet Respir. Med. 2019; 7 (1): 60–68. DOI:10.1016/S2213-2600(18)30339-4.; Richeldi L., Cottin V., du Bois R.M. et al. Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS(®) trials. Respir. Med. 2016; 113: 74–79. DOI:10.1016/j.rmed.2016.02.001.; Авдеев С.Н. Новые возможности терапии идиопатического легочного фиброза. Пульмонология. 2017; 27 (4): 502–514. DOI:10.18093/0869-0189-2017-27-4-502-514.; Авдеев С.Н., Трушенко Н.В. Антифибротическая терапия идиопатического легочного фиброза: соотношение эффективности и безопасности. Медицинский совет. 2018; (15): 131–136. DOI:10.21518/2079-701X-2018-15-131-136.; Noble P.W., Albera C., Bradford W.Z. et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011; 377 (9779): 1760–1769. DOI:10.1016/S0140-6736(11)60405-4.; King T.E., Bradford W.Z., Castro-Bernardini S. et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 2014; 370 (22): 2083–2092. DOI:10.1056/NEJMoa1402582.; Nathan S.D., Albera C., Bradford W.Z. et al. Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis. Lancet Respir. Med. 2017; 5 (1): 33–41. DOI:10.1016/S2213-2600(16)30326-5.; Авдеев С.Н., Чикина С.Ю., Нагаткина О.В. Идиопатический легочный фиброз: новые международные клинические рекомендации. Пульмонология. 2019; 29 (5): 525–552. DOI:10.18093/0869-0189-2019-29-5-525-552.; Richeldi L., Cottin V., Flaherty K.R. et al. Design of the INPULSIS™ trials: Two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis. Respir. Med. 2014; 108 (7): 1023–1030. DOI:10.1016/j.rmed.2014.04.011.; Birring S.S., Kavanagh J.E., Irwin R.S. et al. Treatment of interstitial lung disease associated cough: CHEST guideline and expert panel report. Chest. 2018; 154 (4): 904–917. DOI:10.1016/j.chest.2018.06.038.; Nathan S.D., Costabel U., Albera C. et al. Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment. Respir. Med. 2019; 153: 44–51. DOI:10.1016/j.rmed.2019.04.016.; Polke M, Kondoh Y, Wijsenbeek M. et al. Management of acute exacerbation of idiopathic pulmonary fibrosis in specialised and non-specialised ILD centres around the world. Front. Med. (Lausanne). 2021; 8: 699644. DOI:10.3389/fmed.2021.699644.; Kreuter M., Polke M., Walsh S.L.F. et al. Acute exacerbation of idiopathic pulmonary fibrosis: international survey and call for harmonisation. Eur. Respir. J. 2020; 55 (4): 1901760. DOI:10.1183/13993003.01760-2019.; Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal oxygen therapy trial group. Ann. Intern. Med. 1980; 93 (3): 391–398. DOI:10.7326/0003-4819-93-3-391.; Long-term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party. Lancet. 1981; 317 (8222): 681–686. DOI:10.1016/S0140-6736(81)91970-X.; Faverio P., De Giacomi F., Sardella L. et al. Management of acute respiratory failure in interstitial lung diseases: overview and clinical insights. BMC Pulm. Med. 2018; 18 (1): 70. DOI:10.1186/s12890-018-0643-3.; Dreher M., Ekkernkamp E., Schmoor C. et al. Pulmonary rehabilitation and noninvasive ventilation in patients with hypercapnic interstitial lung disease. Respiration. 2015; 89 (3): 208–213. DOI:10.1159/000369862.; Stern J.B., Mal H., Groussard O. et al. Prognosis of patients with advanced idiopathic pulmonary fibrosis requiring mechanical ventilation for acute respiratory failure. Chest. 2001; 120 (1): 213–219. DOI:10.1378/chest.120.1.213.; Al-Hameed F.M., Sharma S. Outcome of patients admitted to the intensive care unit for acute exacerbation of idiopathic pulmonary fibrosis. Can. Respir. J. 2004; 11 (2): 117–122. DOI:10.1155/2004/379723.; Mollica C., Paone G., Conti V. et al. Mechanical ventilation in patients with end-stage idiopathic pulmonary fibrosis. Respiration. 2010; 79 (3): 209–215. DOI:10.1159/000225932.; Thabut G., Mal H., Castier Y. et al. Survival benefit of lung transplantation for patients with idiopathic pulmonary fibrosis. J. Thorac. Cardiovasc. Surg. 2003; 126 (2): 469–475. DOI:10.1016/s0022-5223(03)00600-7.; Hanada M., Kasawara K.T., Mathur S. et al. Aerobic and breathing exercises improve dyspnea, exercise capacity and quality of life in idiopathic pulmonary fibrosis patients: systematic review and meta-analysis. J. Thorac. Dis. 2020; 12 (3): 1041–1055. DOI:10.21037/jtd.2019.12.27.; King T.E. Jr, Safrin S., Starko K.M. et al. Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis. Chest. 2005; 127 (1): 171–177. DOI:10.1378/chest.127.1.171.; Zappala C.J., Latsi P.I., Nicholson A.G. et al. Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis. Eur. Respir. J. 2010; 35 (4): 830–836. DOI:10.1183/09031936.00155108.; Zieliński M., Sitek P., Ziora D. Idiopathic pulmonary fibrosis coexisting with lung cancer – a review. Adv. Respir. Med. 2018; 86 (6): 319–326. DOI:10.5603/ARM.a2018.0052.; Karampitsakos T., Tzilas V., Tringidou R. et al. Lung cancer in patients with idiopathic pulmonary fibrosis. Pulm. Pharmacol. Ther. 2017; 45: 1–10. DOI:10.1016/j.pupt.2017.03.016.; Costabel U., Crestani B., Wells A., eds. Idiopathic Pulmonary Fibrosis: ERS Monograph. Plymouth: Latimer Trend and Company Limited; 2016. DOI:10.1183/2312508X.erm7116.; Ghofrani H.A., Wiedemann R., Rose F. et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet. 2002; 360 (9337): 895–900. DOI:10.1016/S0140-6736(02)11024-5.; Madden B.P., Allenby M., Loke T.K., Sheth A. A potential role for sildenafil in the management of pulmonary hypertension in patients with parenchymal lung disease. Vascul. Pharmacol. 2006; 44 (5): 372–376. DOI:10.1016/j.vph.2006.01.013.; Collard H.R., Anstrom K.J., Schwarz M.I., Zisman D.A. Sildenafil improves walk distance in idiopathic pulmonary fibrosis. Chest. 2007; 131 (3): 897–899. DOI:10.1378/chest.06-2101.; Olschewski H., Ghofrani H.A., Walmrath D. et al. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am. J. Respir. Crit. Care Med. 1999; 160 (2): 600–607. DOI:10.1164/ajrccm.160.2.9810008.; Minai O.A., Sahoo D., Chapman J.T., Mehta A.C. Vaso-active therapy can improve 6-min walk distance in patients with pulmonary hypertension and fibrotic interstitial lung disease. Respir. Med. 2008; 102 (7): 1015–1020. DOI:10.1016/j.rmed.2008.02.002.; Fulton B.G., Ryerson C.J. Managing comorbidities in idiopathic pulmonary fibrosis. Int. J. Gen. Med. 2015: 8: 309–318. DOI:10.2147/IJGM.S74880.; Raghu G., Yang S.T., Spada C. et al. Sole treatment of acid gastroesophageal reflux in idiopathic pulmonary fibrosis: a case series. Chest. 2006; 129 (3): 794–800. DOI:10.1378/chest.129.3.794.; Linden P.A., Gilbert R.J., Yeap B.Y. et al. Laparoscopic fundoplication in patients with end-stage lung disease awaiting transplantation. J. Thorac. Cardiovasc. Surg. 2006; 131 (2): 438–446. DOI:10.1016/j.jtcvs.2005.10.014.; Lee J.S., Ryu J.H., Elicker B.M. et al. Gastroesophageal reflux therapy is associated with longer survival in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2011; 184 (12): 1390–1394. DOI:10.1164/rccm.201101-0138OC.; Savarino E., Bazzica M., Zentilin P. et al. Gastroesophageal reflux and pulmonary fibrosis in scleroderma: a study using pH-impedance monitoring. Am. J. Respir. Crit. Care Med. 2009; 179 (5): 408–413. DOI:10.1164/rccm.200808-1359OC.; Cano-Jiménez E., Hernández González F., Peloche G.B. Comorbidities and complications in idiopathic pulmonary fibrosis. Med. Sci. 2018; 6 (3): 71. DOI:10.3390/medsci6030071.; Kreuter M., Brunnemer E., Ehlers-Tenenbaum S. et al. Other comorbidities. In: Costabel U., Crestani B., Wells A., eds. Idiopathic pulmonary fibrosis: ERS Monograph. Plymouth: Latimer Trend and Company Limited; 2016: 186–195. DOI:10.1183/2312508X.erm7116.; Mahler D.A., Wells C.K. Evaluation of clinical methods for rating dyspnea. Chest. 1988; 93 (3): 580–586. DOI:10.1378/chest.93.3.580.; https://journal.pulmonology.ru/pulm/article/view/4111

الاتاحة: https://journal.pulmonology.ru/pulm/article/view/4111
https://doi.org/10.18093/0869-0189-2022-32-3-473-495

المؤلفون: I. V. Kudryavtsev, N. M. Lazareva, O. P. Baranova, M. K. Serebriakova, T. P. Ses’, M. M. Ilkovich, A. A. Totolian, И. В. Кудрявцев, Н. М. Лазарева, О. П. Баранова, М. К. Серебрякова, Т. П. Сесь, М. М. Илькович, А. А. Тотолян

المساهمون: Работа выполнена при поддержке гранта РНФ № 22-24-20013

المصدر: Medical Immunology (Russia); Том 24, № 3 (2022); 573-586 ; Медицинская иммунология; Том 24, № 3 (2022); 573-586 ; 2313-741X ; 1563-0625

مصطلحات موضوعية: проточная цитометрия, CD4+T cells, Th cell differentiation, Th17 cell subsets, Th17.1, flow cytometry, Т-хелперы, дифференцировка Т-хелперов, Т-хелперы 17

وصف الملف: application/pdf

Relation: https://www.mimmun.ru/mimmun/article/view/2468/1562; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2468/9068; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2468/9069; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2468/9070; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2468/9071; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2468/9072; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2468/9073; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2468/9074; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2468/9075; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2468/9076; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2468/9077; Визель А.А., Визель И.Ю., Амиров Н.Б. Эпидемиология саркоидоза в Российской Федерации // Вестник современной клинической медицины, 2017. Т. 10, № 5. С. 66-73.; Зурочка А.В., Хайдуков С.В., Кудрявцев И.В., Черешнев В.А. Проточная цитометрия в биомедицинских исследованиях. Екатеринбург: Уральское отделение РАН, 2018. 720 с.; Кудрявцев И.В., Борисов А.Г., Кробинец И.И., Савченко А.А., Серебрякова М.К., Тотолян А.А. Хемокиновые рецепторы на Т-хелперах различного уровня дифференцировки: основные субпопуляции // Медицинская иммунология, 2016. Т. 18, № 3. С. 239-250. doi:10.15789/1563-0625-2016-3-239-250.; Лазарева Н.М., Кудрявцев И.В., Баранова О.П., Серебрякова М.К., Бажанов А.А., Сесь Т.П., Илькович М.М., Тотолян А.А. Анализ субпопуляций В-лимфоцитов в периферической крови больных саркоидозом при разной степени активности заболевания // Медицинская иммунология, 2019. Т. 21, № 6. С. 1081 1098. doi:10.15789/15630625-2019-6-1081-1098.; Agostini C., Cassatella M., Zambello R., Trentin L., Gasperini S., Perin A., Piazza F., Siviero M., Facco M., Dziejman M., Chilosi M., Qin S., Luster A.D., Semenzato G. Involvement of the IP-10 chemokine in sarcoid granulomatous reactions. J. Immunol., 1998, Vol. 161, no. 11, pp. 6413-6420.; Belperio J.A., Dy M., Murray L., Burdick M.D., Xue Y.Y., Strieter R.M., Keane M.P. The role of the Th2 CC chemokine ligand CCL17 in pulmonary fibrosis. J. Immunol., 2004, Vol. 173, no. 7, pp. 4692-4698.; Bennett D., Bargagli E., Refini R.M., Rottoli P. New concepts in the pathogenesis of sarcoidosis. Expert Rev. Respir. Med., 2019, Vol. 13, no. 10, pp. 981-991.; Broos C.E., Hendriks R.W., Kool M. T-cell immunology in sarcoidosis: Disruption of a delicate balance between helper and regulatory T-cells. Curr. Opin. Pulm. Med., 2016, Vol. 22, no. 5, pp. 476-483.; Broos C.E., Koth L.L., van Nimwegen M., In ‘tVeen J.C.C.M., Paulissen S.M.J., van Hamburg J.P., Annema J.T., Heller-Baan R., Kleinjan A., Hoogsteden H.C., Wijsenbeek M.S., Hendriks R.W., van den Blink B., Kool M. Increased T-helper 17.1 cells in sarcoidosis mediastinal lymph nodes. Eur Respir J., 2018, Vol. 51, no. 3, 1701124. doi:10.1183/13993003.01124-2017.; Broquet A., Jacqueline C., Davieau M., Besbes A., Roquilly A., Martin J., Caillon J., Dumoutier L., Renauld J.C., Heslan M., Josien R., Asehnoune K. Interleukin-22 level is negatively correlated with neutrophil recruitment in the lungs in a Pseudomonas aeruginosa pneumonia model. Sci. Rep., 2017, Vol. 7, no. 1, 11010. doi:10.1038/s41598-017-11518-0.; Ding J., Dai J., Cai H., Gao Q., Wen Y. Extensively disturbance of regulatory T cells – Th17 cells balance in stage II pulmonary sarcoidosis. Int. J. Med. Sci., 2017, Vol. 14, no. 11, pp. 1136-1142.; Duhen T., Geiger R., Jarrossay D., Lanzavecchia A., Sallusto F. Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat. Immunol., 2009, Vol. 10, no. 8, pp. 857-863.; Facco M., Baesso I., Miorin M., Bortoli M., Cabrelle A., Boscaro E., Gurrieri C., Trentin L., Zambello R., Calabrese F., Cassatella M.A., Semenzato G., Agostini C. Expression and role of CCR6/CCL20 chemokine axis in pulmonary sarcoidosis. J. Leukoc. Biol., 2007, Vol. 82, no. 4, pp. 946-955.; Facco M., Cabrelle A., Teramo A., Olivieri V., Gnoato M., Teolato S., Ave E., Gattazzo C., Fadini G.P., Calabrese F., Semenzato G., Agostini C. Sarcoidosis is a Th1/Th17 multisystem disorder. Thorax, 2011, Vol. 66, no. 2, pp. 144-150.; Georas S.N., Chapman T.J., Crouser E.D. Sarcoidosis and T-helper cells. Th1, Th17, or Th17.1? Am. J. Respir. Crit. Care Med., 2016, Vol. 193, no 11, pp. 1198-1200.; Golovkin A., Kalinina O., Bezrukikh V., Aquino A., Zaikova E., Karonova T., Melnik O., Vasilieva E., Kudryavtsev I. Imbalanced immune response of T-Cell and B-Cell subsets in patients with moderate and severe COVID-19. Viruses, 2021, Vol. 13, no. 10, 1966. doi:10.3390/v13101966.; Greaves S.A., Atif S.M., Fontenot A.P. Adaptive immunity in pulmonary sarcoidosis and chronic beryllium disease. Front. Immunol., 2020, Vol. 11, 474. doi:10.3389/fimmu.2020.00474.; Hauber H.P., Gholami D., Meyer A., Pforte A. Increased interleukin-13 expression in patients with sarcoidosis. Thorax, 2003, Vol. 58, no. 6, pp. 519-524.; Huang H., Lu Z., Jiang C., Liu J., Wang Y., Xu Z. Imbalance between Th17 and regulatory T-Cells in sarcoidosis. Int. J. Mol. Sci., 2013, Vol. 14, no. 11, pp. 21463-21473.; Kudryavtsev I., Serebriakova M., Starshinova A., Zinchenko Y., Basantsova N., Malkova A., Soprun L., Churilov L.P., Toubi E., Yablonskiy P., Shoenfeld Y. Imbalance in B cell and T follicular helper cell subsets in pulmonary sarcoidosis. Sci Rep., 2020, Vol. 10, no. 1, 1059. doi:10.1038/s41598-020-57741-0.; Kudryavtsev I.V., Lazareva N.M., Baranova O.P., Golovkin A.S., Isakov D.V., Serebriakova M.K., Ses’ T.P., Ilkovich M.M., Totolian A.A. CD39+ expression by regulatory T cells in pulmonary sarcoidosis and Lofgren’s syndrome. Medical Immunology (Russia), 2019, Vol. 21, no. 3. pp. 467-478. doi:10.15789/1563-0625-2019-3-467478.; Kumar P., Rajasekaran K., Palmer J.M., Thakar M.S., Malarkannan S. IL-22: An evolutionary missing-link authenticating the role of the immune system in tissue regeneration. J. Cancer., 2013, Vol. 4, no. 1, pp. 57-65.; Lazareva N.M., Baranova O.P., Kudryavtsev I.V., Isakov D.V., Arsentieva N.A., Liubimova N.E., Ses’ T.P., Ilkovich M.M., Totolian A.A. chemokines CCL17 and CCL22 in sarcoidosis. Medical Immunology (Russia), 2021, Vol. 23, no. 4, pp. 791-798. doi:10.15789/1563-0625-CCA-2340.; Locke L.W., Crouser E.D., White P., Julian M.W., Caceres E.G., Papp A.C., Le V.T., Sadee W., Schlesinger L.S. IL-13-regulated macrophage polarization during granuloma formation in an in vitro human sarcoidosis model. Am. J. Respir. Cell Mol. Biol., 2019, Vol. 60, no. 1, pp. 84-95.; Loke W.S., Herbert C., Thomas P.S. Sarcoidosis: immunopathogenesis and immunological markers. Int. J. Chronic Dis., 2013, Vol. 2013, 928601. doi:10.1155/2013/928601.; Ly N.T.M., Ueda-Hayakawa I., Nguyen C.T.H., Okamoto H. Exploring the imbalance of circulating follicular helper CD4+ T cells in sarcoidosis patients. J. Dermatol. Sci., 2020, Vol. 97, no. 3, pp. 216-224.; Malkova A., Starshinova A., Zinchenko Y., Gavrilova N., Kudryavtsev I., Lapin S., Mazing A., Surkova E., Pavlova M., Belaeva E., Stepanenko Т., Yablonskiy P., Shoenfeld Y. New laboratory criteria of the autoimmune inflammation in pulmonary sarcoidosis and tuberculosis. Clin. Immunol., 2021, Vol. 227, 108724. doi:10.1016/j.clim.2021.108724.; Miedema J.R., Kaiser Y., Broos C.E., Wijsenbeek M.S., Grunewald J., Kool M. Th17-lineage cells in pulmonary sarcoidosis and Löfgren’s syndrome: Friend or foe? J. Autoimmun., 2018, Vol. 87, pp. 82-96.; Moller D.R. Cells and cytokines involved in the pathogenesis of sarcoidosis. Sarcoidosis Vasc. Diffuse Lung Dis., 1999, Vol. 16, no. 1, pp. 24-31.; Mortaz E., Rezayat F., Amani D., Kiani A., Garssen J., Adcock I.M., Velayati A. The Roles of T Helper 1, T Helper 17 and кegulatory T Cells in the pathogenesis of sarcoidosis. Iran J. Allergy Asthma Immunol., 2016, Vol. 15, no. 4, pp. 334-339.; Nguyen C.T.H., Kambe N., Ueda-Hayakawa I., Kishimoto I., Ly N.T.M., Mizuno K., Okamoto H. TARC expression in the circulation and cutaneous granulomas correlates with disease severity and indicates Th2-mediated progression in patients with sarcoidosis. Allergol. Int., 2018, Vol. 67, no. 4, pp. 487-495.; Nguyen Q.P., Deng T.Z., Witherden D.A., Goldrath A.W. Origins of CD4+ circulating and tissue-resident memory T-cells. Immunology, 2019, Vol. 157, no. 1, pp. 3-12.; Palchevskiy V., Hashemi N., Weigt S.S., Xue Y.Y., Derhovanessian A., Keane M.P., Strieter R.M., Fishbein M.C., Deng J.C., Lynch J.P., Elashoff R., Belperio J.A. Immune response CC chemokines CCL2 and CCL5 are associated with pulmonary sarcoidosis. Fibrogenesis Tissue Repair, 2011, Vol. 4, 10. doi:10.1186/1755-1536-4-10.; Paulissen S.M., van Hamburg J.P., Dankers W., Lubberts E. The role and modulation of CCR6+ Th17 cell populations in rheumatoid arthritis. Cytokine, 2015, Vol. 74, no. 1, pp. 43-53.; Ramstein J., Broos C.E., Simpson L.J., Ansel K.M., Sun S.A., Ho M.E., Woodruff P.G., Bhakta N.R., Christian L., Nguyen C.P., Antalek B.J., Benn B.S., Hendriks R.W., van den Blink B., Kool M., Koth L.L. IFN-γproducing T-Helper 17.1 Cells are increased in sarcoidosis and are more prevalent than T-Helper type 1 Cells. Am. J. Respir. Crit. Care Med., 2016, Vol. 193, no. 11, pp. 1281-1291.; Sakthivel P., Bruder D. Mechanism of granuloma formation in sarcoidosis. Curr. Opin. Hematol., 2017, Vol. 24, no. 1, pp. 59-65.; Sallusto F., Zielinski C.E., Lanzavecchia A. Human Th17 subsets. Eur. J. Immunol., 2012, Vol. 42, no. 9, pp. 2215-2220.; Shamaei M., Mortaz E., Pourabdollah M., Garssen J., Tabarsi P., Velayati A., Adcock I.M. Evidence for M2 macrophages in granulomas from pulmonary sarcoidosis: A new aspect of macrophage heterogeneity. Hum. Immunol., 2018, Vol. 79, no. 1, pp. 63-69.; Shigehara K., Shijubo N., Ohmichi M., Takahashi R., Kon S., Okamura H., Kurimoto M., Hiraga Y., Tatsuno T., Abe S., Sato N. IL-12 and IL-18 are increased and stimulate IFN-gamma production in sarcoid lungs. J. Immunol., 2001, Vol. 166, no. 1, pp. 642-649.; Simonian P.L., Wehrmann F., Roark C.L., Born W.K., O’Brien R.L., Fontenot A.P. γδ T cells protect against lung fibrosis via IL-22. J. Exp. Med., 2010, Vol. 207, no. 10, pp. 2239-2253.; Starshinova A.A., Malkova A.M., Basantsova N.Y., Zinchenko Y.S., Kudryavtsev I.V., Ershov G.A., Soprun L.A., Mayevskaya V.A., Churilov L.P., Yablonskiy P.K. Sarcoidosis as an Autoimmune Disease. Front. Immunol., 2020, Vol. 10, 2933. doi:10.3389/fimmu.2019.02933.; Tarasidis A., Arce S. Immune response biomarkers as indicators of sarcoidosis presence, prognosis, and possible treatment: An immunopathogenic perspective. Autoimmun Rev., 2020, Vol. 19, no. 3, 102462. doi:10.1016/j.autrev.2020.102462.; Ten Berge B., Paats M.S., Bergen I.M., van den Blink B., Hoogsteden H.C., Lambrecht B.N., Hendriks R.W., Kleinjan A. Increased IL-17A expression in granulomas and in circulating memory T cells in sarcoidosis. Rheumatology (Oxford), 2012, Vol. 51, no. 1, pp. 37-46.; Wacleche V.S., Goulet J.P., Gosselin A., Monteiro P., Soudeyns H., Fromentin R., Jenabian M.A., Vartanian S., Deeks S.G., Chomont N., Routy J.P., Ancuta P. New insights into the heterogeneity of Th17 subsets contributing to HIV-1 persistence during antiretroviral therapy. Retrovirology, 2016, Vol. 13, no. 1, 59. doi:10.1186/s12977-0160293-6.; Zhang H., Costabel U., Dai H. The role of diverse immune cells in sarcoidosis. Front. Immunol., 2021, Vol. 12, 788502. doi:10.3389/fimmu.2021.788502.; https://www.mimmun.ru/mimmun/article/view/2468

الاتاحة: https://www.mimmun.ru/mimmun/article/view/2468
https://doi.org/10.15789/1563-0625-PBT-2468

المؤلفون: T. A. Fedorova, P. K. Yablonsky, A. L. Bulyanina, N. I. Alexandrova, M. M. IIkovich, L. N. Novikova, E. V. Simonenko, T. A. Stepanenko, Т. А. Федорова, П. К. Яблонский, А. Л. Буляница, Н. И. Александрова, М. М. Илькович, Л. H. Новикова, Е. В. Симоненко, Т. А. Степаненко

المصدر: PULMONOLOGIYA; № 2 (2001); 25-30 ; Пульмонология; № 2 (2001); 25-30 ; 2541-9617 ; 0869-0189

وصف الملف: application/pdf

Relation: https://journal.pulmonology.ru/pulm/article/view/2791/2204; Большее Л.Н., Смирнов И.В. Таблицы математической статистики. М.: Наука; 1983.; Демидович Б.П., Марон И.А., Шувалова Э.З. Численные методы анализа / Под ред. Б. П. Демидовича. М.: Физматгиз; 1963.; Егурнов И.И., Александров А.Л., Семенова Л.А., Веселова Е.В. Исходы ИФА и их связь с показателями легочной гемодинамики и дыхания. Пробл. туб. 1987; 7: 10-12.; Илькович М.М. Идиопатический фиброзирующий альвеолит. В кн. Палеев H. Р. (ред.) Болезни органов дыхания. М.: Медицина; 1990; т. 4: 64-89.; Левашев Ю.Н., Яблонский П.К., Ст епаненко Т.А. и др. Отбор реципиентов для трансплантации легких. Пульмонология 1998; 1: 56-64.; Сильвест ров В.П., Суворов Ю.А., Семин С.И., Марциновский В.Ю. Хроническое легочное сердце: механизмы формирования и прогрессирования. Тер. арх. 1990; 3: 103-108.; Agusti С., Xaubet A., Agusti A.G.N. et al. Clinical and functional assessment of patients with idiopathic pulmonary fibrosis: results of a 3 year follow-up. Eur. Respir. J. 1994; 7 (4): 643-650.; D'Armini A.M., Callegari G., Vitulo P. et al. Risk factors for early death in patients awaiting heart-lung or lung transplantation. Transplantation 1998; 66 (1): 123-127.; Grossman R.F., Frost A., Zamel N. et al. Results of single-lung transplantation for bilateral pulmonary fibrosis. N. Engl. J. Med. 1990; 322 (11): 727-733.; Harari S., Simonneau G., De Juli E. et al. Prognostic value of pulmonary hypertension in patients with chronic interstitial lung disease referred for lung or heart-lung transplantation. J. Heart Lung Transplant. 1997; 16 (4): 460-463.; Katzenstein A.-L. A., Myers J.L. Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am. J. Respir. Crit. Care Med. 1998; 157 (4, pt 1): 1301-1315.; Mapel D.W., Hunt W.C., Utton R. et al. Idiopathic pulmonary fibrosis: survival in population-based and hospital-based cohorts. Thorax 1998; 53 (6): 469-476.; Panos R.J., Mortenson R.L., Niccoli A., King T.E. Jr. Clinical deterioration in patients with idiopathic pulmonary fibrosis: causes and assessment. Am. J. Med. 1990; 88 (4): 396-404.; Turner-Warwick М., Burrows B., Johnson A. Cryptogenic fibrosing alveolitis: clinical features and their influence on survival. Thorax 1980; 35: 171-180.; Watters L.C., King T.E. et al. A clinical, radiographic and physiologic scoring system for the longitudinal assessment of patients with idiopathic pulmonary fibrosis. Am. Rev. Respir. Dis. 1986; 133 (1): 97-103.; https://journal.pulmonology.ru/pulm/article/view/2791

الاتاحة: https://journal.pulmonology.ru/pulm/article/view/2791

المؤلفون: M. M. Ilkovich, М. М. Илькович

المصدر: PULMONOLOGIYA; № 2 (1998); 89-91 ; Пульмонология; № 2 (1998); 89-91 ; 2541-9617 ; 0869-0189

وصف الملف: application/pdf

Relation: https://journal.pulmonology.ru/pulm/article/view/3245/2641; https://journal.pulmonology.ru/pulm/article/view/3245

الاتاحة: https://journal.pulmonology.ru/pulm/article/view/3245

المؤلفون: A. G. Chuchalin, L. M. Ogorodova, F. I. Petrovsky, A. V. Zhestkov, M. M. IIkovich, T. I. Martynenko, A. P. Rebrov, L. Yu. Reutova, Yu. A. Tereshchenko, R. S. Fassakhov, B. А. Chernyak, E. S. Kulikov, А. Г. Чучалин, Л. М. Огородова, Ф. И. Петровский, А. В. Жестков, М. М. Илькович, Т. И. Мартыненко, А. П. Ребров, Л. Ю. Реутова, Ю. А. Терещенко, Р. С. Фассахов, Б. А. Черняк, Е. С. Куликов

المصدر: PULMONOLOGIYA; № 6 (2004); 68-77 ; Пульмонология; № 6 (2004); 68-77 ; 2541-9617 ; 0869-0189 ; 10.18093/0869-0189-2004-0-6

وصف الملف: application/pdf

Relation: https://journal.pulmonology.ru/pulm/article/view/2487/1933; Global Initiative for Asthma, 2003. The global burden of asthma: A summary. [Электронный ресурс], 2003. Доступ: http://207.159.65.33/wadsetup/materials_03/sum.doc; World Health Organization. WHO fact sheet no 206: Bronchial asthma. WHO. [Электронный ресурс], 2000. Доступ: http://www.who.int/inf-fs/en/fact206.html; Global Initiative for Asthma. Workshop Report [Электронный ресурс], 2002. Доступ: http://www.ginasthma.com/workshop.pdf; AIRE, 1999. Asthma insights and reality in Europe: Executive summary. [Электронный ресурс], 1999. Доступ: http://www.asthma.ac.psiweb.com/executive/mn_exec_summary_index.html; Asthma in America, 1998. Asthma in America survey: Executive summary. [Электронный ресурс], 1998. Доступ: http://www.asthmainamerica.com/execsum_over.htm; Difficult/therapy-resistant asthma. ERS Task Force on Difficult/therapy-resistant asthma. Eur. Respir. J. 1999; 13: 1198-1208.; Огородова Л.М., Кобякова O.C., Петровский Ф.И. и др. Новые подходы к ведению пациентов с тяжелой неконтролируемой бронхиальной астмой (результаты открытого многоцентрового рандомизированного исследования "BRILLIANT" — часть I). Аллергология 2002; 1: 3-11.; Чучалин А.Г., Черняк Б.А., Медникова О.Б. Эффективность сочетанного применения флутиказона пропионата и сальмете-рола при 18-месячной терапии стероидзависимой бронхиальной астмы. Пульмонология 1998; 3: 64-70.; Shrewsbury S., Pyke S., Britton М. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). Br. Med. J. 2000; 320: 1368-1373.; Lim S., Jatakanon A., Gordon D. et at. Comparison of high dose inhaled steroids, low dose inhaled steroids plus low dose theophylline, and low dose inhaled steroids alone in chronic asthma in general practice. Thorax 2000; 55: 837-841.; Bateman E.D., Boushey H.A., Bousquet J. et at. Can guideline-defined asthma control be achieved? The gaining optimal asthma control study. Am. J. Respir. Crit. Care Med. 2004; 170: 836-844.; https://journal.pulmonology.ru/pulm/article/view/2487

الاتاحة: https://journal.pulmonology.ru/pulm/article/view/2487

المؤلفون: O. A. Sukhovskaya, M. M. Ilkovich, V. A. Ignatiev, О. А. Суховская, М. М. Илькович, В. А. Игнатьев

المصدر: PULMONOLOGIYA; № 1 (2003); 96-100 ; Пульмонология; № 1 (2003); 96-100 ; 2541-9617 ; 0869-0189 ; 10.18093/0869-0189-2003-0-1

وصف الملف: application/pdf

Relation: https://journal.pulmonology.ru/pulm/article/view/2711/2140; Бримкулов H.H., Jones Р. W., Калиева А.Д. Валидизация русской версии краткого опросника AQ20 для исследования качества жизни у больных астмой. Пульмонология 1999; 3: 14-21.; Бримкулов H.H., Дуйсенова Ж., Калиева А.Д. Качество жизни у больных бронхиальной астмой: влияние недокромила натрия (тайледа). Там же 45-51.; Принципы обеспечения качества. Отчет о совещании ВОЗ в Барселоне. (Сост. отчета W.F.Jessee). М.: Медицина; 1991.; Сенкевич Н.Ю., Амелина E.Ю. Качество жизни взрослых больных муковисцидозом: факты и гипотезы. Пульмонология 1999; 3: 51-57.; Суховская O.A., Горбенко И.А. Сравнительное исследование качества жизни здоровых и больных бронхиальной астмой. В кн.: Исследование качества жизни в медицине. СПб.: ВМА: 2000. 131-133.; Чавпецов В.Ф., Гришин В.В., Семенов В.Ю., Глущенко П.П. (ред.) Медицинское страхование. Экспертиза качества медицинской помощи в системе обязательного медицинского страхования. (Проблемы, задачи и подходы к их решению): Метод. пособие. М.: Знание; 1995.; Шмелев Е.И., Беда М.В., Jones P.W. и др. Качество жизни больных хроническими обструктивными заболеваниями легких. Пульмонология 1998; 3: 79-81.; Aaronson N.K., Ahmedzai S., Bergman В. et al. The European organization for research and treatment of cancer QLQ-C30: a quality of life instrument for use in international clinical trials in oncology. J. Natl. Cancer Inst. 1993; 85 (5): 365-375.; Bousquet J., Knani J., Dhivert H. et al. Quality of life in asthma. Internal consistency and validity of the SF-36 questionnaire. Am. J. Respir. Crit. Care Med. 1994; 149: 371-375.; Bullinger М., Alonso J., Apolone G. et al. Jr. Translating health status questionnaires and evaluating their quality: the IQOLA Project approach. International quality of life assessment. J. Clin. Epidemiol. 1998; 51: 913-23.; Celia D.F. Methods and problems in measuring quality of life. Support. Care Cancer 1995; 3: 11-22.; Chang J.A., Curtis J.R., Patrick D.L., Raghu G. Assessment of health-related quality of life in patients with interstitial lung disease. Chest 1999; 116 (5): 1175.; Cleary P.O., Greenfield S., McNeil B.J. Assessing quality of life after surgery. Control Clin.Trials 1991; 12: 189-203.; Coates A., Gebski V., Signorini D. et. al. Prognostic value of quality of life scores during chemotherapy for advanced breast cancer. J. Clin. Oncol. 1992; 10: 1833-1838.; Corcoran W.E., Durham C.F. Quality of life as an outcomebased evaluation of coronary artery bypass graft critical paths using the SF-36. Qua). Manag. Hlth Care 2000; 8 (2): 72-81.; Dempster М., Donelley M. Measuring the health related quality of life of people with ischaemic heart disease. Heart 2000; 83 (6): 641-644.; De Vries J., Drent М., Van Heck G.L., Wouters E.F. Quality of life in sarcoidosis: a comparison between members of a patient organization and a random sample. Sarcoidos. Vase. Diffuse Lung Dis. 1998; 15 (2): 183-188.; De Vries J., Van Heck G.L., Drent M. Gender differences in sarcoidosis: symptoms, quality of life, and medical consumption. Women Hlth 1999; 30 (2): 99-114.; Ferrer М., Alonso J., Prieto L. et al. Validity and reliability of the St George's Respiratory Questionnaire after adaptation to a different language and culture: the Spanish example. Eur. Respir. J. 1996; 9 (6): 1160-1166.; Gee L., Abbott J., Conway S.P. et al. Development of a disease specific health related quality of life measure for adult and adolescent with cystic fibrosis. Thorax 2000; 55 (11): 946-954.; Glaspy J., Bukowsky R., Steinberg D. Impact of therapy with epoetin alia on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrite study group. J. Clin. Oncol. 1997; 15: 1218-1234.; Jackson-Triche M .E., Greee Sullivan J., Wells K.B. et al. Depression and health-related quality of life in ethnic minorities seeking care in general medical settings. J. Affect. Disord. 2000; 58 (2): 89-97.; Johnson J.A., Connolly М., Zuberbuhler P., Brown N.E. Healthrelated quality of life for adult with cystic fibrosis: a regression approach to assessing the impact of recombinant human DNase. Pharmacotherapy 2000; 20 (10): 1167-1174.; Jones P.W. Quality of life measurement: the value of standartion. J. Eur. Respir. Rev. 1997; 7 (42): 46-52.; Juniper E.F., Guyatt G.H., Epstein R.S. et al. Evalution of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax 1992; 47: 76-83.; Kaasa S., Mastekaasa A., Lund E. Prognostic factors for patients with inoperable non-small lung cancer, limited disease. Radiother. Oncol. 1989; 15L: 235-242.; Quittner A.L. Measurement of quality of life in cystic fibrosis. Curr. Opin. Pulm. Med. 1998; 4 (6): 326-331.; Salek M .S., Luscombe D.K. Health-related quality of life: a review. J. Drug Dev. 1992; 5 (3): 137-153.; Sedman A.D., Porteney R., Yao T.J. et al. Quality of life in Phase II Trials: a study of methodology and predictive value in patients with advance breast cancer treated with Paclitaxel plus granulocyte colony stimulating factor. J. Natl. Cancer Inst. 1995; 87: 1316-1322.; Soran A., ChelLuri L., Lee K.K., Tisherman S.A. Outcome and Quality of Life of Patients with Acute Pancreatitis Requiring Intensive Care. J. Surg. Res. 2000; 91 (1): 89-94.; Spilker B., ed. Quality of life assessments in clinical trials. New York: Raven Press Ltd; 1990.; Spilker B. Quality of life pharmacoeconomics in clinical trials. 2nd ed. Philadelphia: Lippincott-Raven; 1996.; Ware J.E., Sherbourne C.D. The MOS 36-item short form health survey (SF-36): 1. Conceptuel framework and item selection. Med. Care 1992; 30: 473-483.; Ware J.E., Snow K.K., Kosinski M. SF-36 health survey: manual and interpretation guide. Boston; 1993.; Wimsberger R.M., de Vries J., Breteler M.H. et al. Evalution of quality of life in sarcoidosis patients. Respir. Med. 1998; 92 (5): 750-756.; World Healh Health Organization. Basic documents. 26th ed. Geneva: WHO; 1976; vol.l.; https://journal.pulmonology.ru/pulm/article/view/2711

الاتاحة: https://journal.pulmonology.ru/pulm/article/view/2711

المؤلفون: N. M. Lazareva, O. P. Baranova, I. V. Kudryavtsev, N. A. Arsentieva, N. E. Liubimova, T. P. Ses’, M. M. Ilkovich, Areg A. Totolian, Н. М. Лазарева, О. П. Баранова, И. В. Кудрявцев, Н. А. Арсентьева, Н. Е. Любимова, Т. П. Сесь, М. М. Илькович, Арег А. Тотолян

المصدر: Medical Immunology (Russia); Том 23, № 1 (2021); 73-86 ; Медицинская иммунология; Том 23, № 1 (2021); 73-86 ; 2313-741X ; 1563-0625

مصطلحات موضوعية: плазма крови, chemokines, CXCL9, CXCL10, CXCL11, CXCR3 ligands, peripheral blood, plasma, хемокины, CXCR3 лиганды

وصف الملف: application/pdf

Relation: https://www.mimmun.ru/mimmun/article/view/2181/1346; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2181/7378; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2181/7379; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2181/7380; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2181/7381; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2181/7382; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2181/7383; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2181/7384; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2181/7385; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2181/7386; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2181/7387; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2181/7388; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2181/7389; Арсентьева Н.А., Семенов А.В., Жебрун Д.А., Васильева Е.В., Тотолян А.А. Роль хемокинового рецептора CXCR3 и его лигандов при некоторых иммунопатологических состояниях // Медицинская иммунология, 2019. Т. 21, № 4. С. 617-632. doi:10.15789/1563-0625-2019-4-617-632.; Баранова О.П., Кудрявцев И.В., Лазарева Н.М., Серебрякова М.К., Сесь Т.П., Илькович М.М., Тотолян Арег А. Цитотоксические Т-лимфоциты при хроническом течении саркоидоза // Российский иммунологический журнал, 2018. Т. 12 (21), № 4. С. 605-608.; Илькович М.М. Диффузные паренхиматозные заболевания легких. М.: ГЕОТАР-Медиа, 2021. 440 с. [Ilkovich M.M. Diffuse parenchymal lung diseases]. Moscow: GEOTAR-Media, 2021. 440 p.; Кудрявцев И.В., Борисов А.Г., Кробинец И.И., Савченко А.А., Серебрякова М.К., Тотолян А.А. Хемокиновые рецепторы на Т-хелперах различного уровня дифференцировки: основные субпопуляции // Медицинская иммунология, 2016. T. 18, № 3. С. 239-250. doi:10.15789/1563-0625-2016-3-239-250.; Лазарева Н.М., Кудрявцев И.В., Баранова О.П., Серебрякова М.К., Сесь Т.П., Илькович М.М., Тотолян Арег А. Субпопуляционный состав цитотоксических Т-лимфоцитов периферической крови при саркоидозе // Российский иммунологический журнал, 2018. Т. 12 (21), № 3. С. 348-353.; Лазарева Н.М., Кудрявцев И.В., Баранова О.П., Серебрякова М.К., Сесь Т.П., Илькович М.М., Тотолян Арег А. Анализ субпопуляций В-лимфоцитов в периферической крови больных саркоидозом при разной степени активности заболевания // Медицинская иммунология, 2019. Т. 21, № 6. С. 1081-1098. doi:10.15789/1563-0625-2019-6-1081-1098.; Лазарева Н.М., Баранова О.П., Кудрявцев И.В., Арсентьева Н.А., Любимова Н.Е., Сесь Т.П., Илькович М.М., Тотолян Арег А. Особенности цитокинового профиля при саркоидозе // Медицинская иммунология, 2020. Т. 22, № 5. С. 993-1002. doi:10.15789/1563-0625-FOC-2064.; Aksoy M.O., Yang Y., Ji R., Reddy P.J., Shahabuddin S., Litvin J., Rogers T.J., Kelsen S.G. CXCR3 surface expression in human airway epithelial cells: cell cycle dependence and effect on cell proliferation. Am. J. Physiol. Lung Cell Mol. Physiol., 2006, Vol. 290, no. 5, pp. 909-918.; Antonelli A., Ferrari S.M., Frascerra S. et al. Increase of circulating CXCL9 and CXCL11 associated with euthyroid or subclinically hypothyroid autoimmune thyroiditis. J. Clin. Endocrinol. Metab., 2011, Vol. 96, pp. 1859-1863.; Antonelli A., Ferrari S.M., Frascerra S. et al. Circulating chemo-kine (CXC motif) ligand (CXCL) 9 is increased in aggressive chronic autoimmune thyroiditis, in association with CXCL10. Cytokine, 2011, Vol. 55, pp. 288-293.; Arger N.K., Ho M., Woodruff P.G., Koth L.L. Serum CXCL11 correlates with pulmonary outcomes and disease burden in sarcoidosis. Respir. Med., 2019, Vol. 152, pp. 89-96.; Arger N.K., Ho M.E., Allen I.E., Benn B.S., Woodruff P.G., Koth L.L. CXCL9 and CXCL10 are differentially associated with systemic organ involvement and pulmonary disease severity in sarcoidosis. Respir. Med., 2020, Vol. 161, 105822. doi:10.1016/j.rmed.2019.105822.; Bertolini T.B., Piñeros A.R., Prado R.Q., Gembre A.F., Ramalho L.N.Z., Alves-Filho J.C., Bonato V.L.D. CCR4-dependent reduction in the number and suppressor function of CD4+Foxp3+ cells augments IFN-γ-mediated pulmonary inflammation and aggravates tuberculosis pathogenesis. Cell Death Dis., 2018, Vol. 10, no. 1, 11. doi:10.1038/s41419-018-1240-3.; Broos C.E., van Nimwegen M., Hoogsteden H.C., Hendriks R.W., Kool M., van den Blink B. Granuloma formation in pulmonary sarcoidosis. Front. Immunol., 2013, Vol. 10, no. 4, 437. doi:10.3389/fimmu.2013.00437.; Chappell A.G., Cheung W.Y., Hutchings H.A. Sarcoidosis: a long-term follow up study. Sarcoidosis Vasc. Diffuse. Lung. Dis., 2000, Vol. 17, no. 2, pp. 167-173.; Cole K.E., Strick C.A., Paradis T.J., Ogborne K.T., Loetscher M., Gladue R.P., Lin W., Boyd J.G., Moser B., Wood D.E., Sahagan B.G., Neote K. Interferoninducible T cell alpha chemoattractant (I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3. J. Exp. Med., 1998, Vol. 187, no. 12, pp. 2009-2021.; Colvin R.A., Campanella G.S., Sun J., Luster A.D. Intracellular domains of CXCR3 that mediate CXCL9, CXCL10, and CXCL11 function. J. Biol. Chem., 2004, Vol. 279, no. 29, pp. 30219-30227.; Cooke G., Govender P., Watson C.J., Armstrong M.E., O’Dwyer D.N., Keane M.P., King R., Tynan A., Dunn M., Donnelly S.C. Sarcoidosis, alveolar β-actin and pulmonary fibrosis. QJM, 2013, Vol. 106, no. 10, pp. 897-902.; Fallahi P., Ferri C., Ferrari S.M. et al. Cytokines and HCV-related disorders. Clin. Dev. Immunol., 2012, Vol. 2012, 468107. doi:10.1155/2012/468107.; Garcia-Lopez M.A., Sanchez-Madrid F., Rodriguez-Frade J.M., Mellado M., Acevedo A., Garcia M.I., Albar J.P., Martinez C., Marazuela M. CXCR3 chemokine receptor distribution in normal and inflamed tissues: expression on activated lymphocytes, endothelial cells, and dendritic cells. Lab. Invest., 2001, Vol. 81, pp. 409-418.; Geyer A.I., Kraus T., Roberts M., Wisnivesky J., Eber C.D., Hiensch R., Moran T.M. Plasma level of interferon γ induced protein 10 is a marker of sarcoidosis disease activity. Cytokine, 2013, Vol. 64, no. 1, pp. 152-157.; Groom J.R., Luster A.D. CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunol. Cell Biol., 2011, Vol. 89, no. 2, pp. 207-215.; Hunninghake G.W., Costabel U., Ando M., Baughman R., Cordier J.F., du Bois R., Eklund A., Kitaichi M., Lynch J., Rizzato G., Rose C., Selroos O., Semenzato G., Sharma O.P. ATS/ERS/WASOG statement on sarcoidosis. American thoracic society/European respiratory society/world association of sarcoidosis and other granulomatous disorders. Sarcoidosis Vasc. Diffuse. Lung. Dis., 1999, Vol. 16, no. 2, pp. 149-173.; Jiang D., Huang X., Geng J., Dong R., Li S., Liu Z., Wang C., Dai H. Pulmonary fibrosis ina mouse model of sarcoid granulomatosis induced by booster challenge with Propionibacterium acnes. Oncotarget, 2016, Vol. 7, no. 23, pp. 33703-33714.; Kishi J., Nishioka Y., Kuwahara T., Kakiuchi S., Azuma M., Aono Y., Makino H., Kinoshita K., Kishi M., Batmunkh R., Uehara H., Izumi K., Sone S. Blockade of Th1 chemokine receptors ameliorates pulmonary granulomatosis in mice. Eur. Respir. J., 2011, Vol. 38, no. 2, pp. 415-424.; Kriegova E., Fillerova R., Tomankova T., Hutyrova B., Mrazek F., Tichy T., Kolek V., du Bois R.M., Petrek M. T-helper cell type-1 transcription factor T-bet is upregulated in pulmonary sarcoidosis. Eur. Respir. J., 2011, Vol. 38, no. 5, pp. 1136-1144.; Lacotte S., Brun S., Muller S. et al. CXCR3, inflammation, and autoimmune diseases. Ann. N. Y. Acad. Sci., 2009, Vol. 1173, pp. 310-317.; Lasagni L., Francalanci M., Annunziato F., Lazzeri E., Giannini S., Cosmi L., Sagrinati C., Mazzinghi B., Orlando C., Maggi E., Marra F., Romagnani S., Serio M., Romagnani P. An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4. J. Exp. Med., 2003, Vol. 197, pp. 1537-1549.; Lee E.Y., Lee Z.H., Song Y.W. The interaction between CXCL10 and cytokines in chronic inflammatory arthritis. Autoimmun. Rev., 2013, Vol. 12, pp. 554-557.; Medoff B.D., Wain J.C., Seung E., Jackobek R., Means T.K., Ginns L.C., Farber J.M., Luster A.D. CXCR3 and its ligands in a murine model of obliterative bronchiolitis: regulation and function. J. Immunol., 2006, Vol. 176, no. 11, pp. 7087-7095.; Mollers M., Aries S.P., Dromann D., Mascher B., Braun J., Dalhoff K. Intracellular cytokine repertoire in different T cell subsets from patients with sarcoidosis. Thorax, 2001, Vol. 56, no. 6, pp. 487-493.; Muehlinghaus G., Cigliano L., Huehn S., Peddinghaus A., Leyendeckers H., Hauser A.E. Regulation of CXCR3 and CXCR4 expression during terminal differentiation of memory B cells into plasma cells. Blood, 2005, Vol. 105, pp. 3965-3971.; Nishioka Y., Manabe K., Kishi J. et al. CXCL9 and 11 in patients with pulmonary sarcoidosis: a role of alveolar macrophages. Clin. Exp. Immunol., 2007, Vol. 149, pp. 317-326.; Nureki S., Miyazaki E., Ando M., Ueno T., Fukami T., Kumamoto T., Sugisaki K., Tsuda T. Circulating levels of both Th1 and Th2 chemokines are elevated in patients with sarcoidosis. Respir. Med., 2008, Vol. 102, no. 2, pp. 239-247.; Ohmori Y., Wyner L., Narumi S., Armstrong D., Stoler M., Hamilton T.A. Tumor necrosis factor-alpha induces cell type and tissue-specific expression of chemoattractant cytokines in vivo. Am. J. Pathol., 1993, Vol. 142, no. 3, pp. 861-870.; Piotrowski W.J., Młynarski W., Fendler W. et al. Chemokine receptor CXCR3 ligands in bronchoalveolar lavage fluid: associations with radiological pattern, clinical course, and prognosis in sarcoidosis. Pol. Arch. Med. Wewn., 2014, Vol. 124, pp. 395-402.; Prasse A., Georges C.G., Biller H., Hamm H., Matthys H., Luttmann W., Virchow J.C. Th1 cytokine pattern in sarcoidosis is expressed by bronchoalveolar CD4+ and CD8+ T cells. Clin. Exp. Immunol., 2000, Vol. 122, no. 2, pp. 241-248.; Proost P., Verpoest S., Van de Borne K., Schutyser E., Struyf S., Put W., Ronsse I., Grillet B., Opdenakker G., van Damme J. Synergistic induction of CXCL9 and CXCL11 by Toll-like receptor ligands and interferon-gamma in fibroblasts correlates with elevated levels of CXCR3 ligands in septic arthritis synovial fluids. J. Leukoc. Biol., Vol. 75, no. 5, pp. 777-784.; Proost P., Vynckier A.K., Mahieu F., Put W., Grillet B., Struyf S., Wuyts A., Opdenakker G., Van Damme J. Microbial Toll-like receptor ligands differentially regulate CXCL10/IP-10 expression in fibroblasts and mononuclear leukocytes in synergy with IFN-gamma and provide a mechanism for enhanced synovial chemokine levels in septic arthritis. Eur. J. Immunol., 2003, Vol. 33, no. 11, pp. 3146-3153.; Ragusa F. Sarcoidosis and Th1 chemokines. Clin Ter., 2015, Vol. 166, no. 1, pp. e72-e76.; Ragusa F. Sarcoidosis and the Th1 chemokine MIG. Clin Ter., 2018, Vol. 169, no. 6, pp. e308-e313.; Sakthivel P., Bruder D. Mechanism of granuloma formation in sarcoidosis. Curr. Opin. Hematol., 2017, Vol. 24, no. 1, pp. 59-65.; Smit M.J., Verdijk P., van der Raaij-Helmer E.M. et al. CXCR3-mediated chemotaxis of human T cells is regulated by a Gi- and phospholipase C-dependent pathway and not via activation of MEK/p44/p42 MAPK nor Akt/PI-3 kinase. Blood, 2003, Vol. 102, pp. 1959-1965.; Strieter R.M., Burdick M.D., Gomperts B.N., Belperio J.A., Keane M.P. CXC chemokines in angiogenesis. Cytokine Growth Factor Rev., 2005, Vol. 16, no. 6, pp. 593-609.; Su R., Nguyen M.L., Agarwal M.R., et al. Interferon-inducible chemokines reflect severity and progression in sarcoidosis. Respir. Res., 2013, Vol. 14, 121. doi:10.1186/1465-9921-14-121.; Takeuchi M., Oh-I K., Suzuki J. et al. Elevated serum levels of CXCL9/monokine induced by interferon-gamma and CXCL10/interferon-gamma-inducible protein-10 in ocular sarcoidosis. Invest. Ophthalmol. Vis. Sci., 2006, Vol. 47, pp. 1063-1068.; Torraca V., Cui C., Boland R., Bebelman J.P., van der Sar A.M., Smit M.J., Siderius M., Spaink H.P., Meijer A.H. The CXCR3-CXCL11 signaling axis mediates macrophage recruitment and dissemination of mycobacterial infection. Dis. Model. Mech., 2015, Vol. 8, no. 3, pp. 253-269.; van Raemdonck K., van den Steen P.E., Liekens S., van Damme J., Struyf S. CXCR3 ligands in disease and therapy. Cytokine Growth Factor Rev., 2015, Vol. 26, no. 3, pp. 311-327.; Xanthou G., Duchesnes C.E., Williams T.J., Pease J.E. CCR3 functional responses are regulated by both CXCR3 and its ligands CXCL9, CXCL10 and CXCL11. Eur. J. Immunol., 2003, Vol. 33, no. 8, pp. 2241-2250.; https://www.mimmun.ru/mimmun/article/view/2181

الاتاحة: https://www.mimmun.ru/mimmun/article/view/2181
https://doi.org/10.15789/1563-0625-CCR-2181

المؤلفون: K. A. Zykov, S. I. Ovcharenko, S. N. Avdeev, A. V. Zhestkov, M. M. Il'kovich, V. A. Nevzorova, U. R. Farkhutdinov, R. F. Khamitov, A. V. Rvacheva, A. G. Chuchalin, К. А. Зыков, С. И. Овчаренко, С. Н. Авдеев, А. В. Жестков, М. М. Илькович, В. А. Невзорова, У. Р. Фархутдинов, Р. Ф. Хамитов, А. В. Рвачева, А. Г. Чучалин

المساهمون: The POPE study is funded by the Ludwig Boltzmann Institute for COPD and Respiratory Epidemiology (Vienna, Austria). This research institute received an unlimited research grant from Boehringer Ingelheim, which provided partial support for this study, but did not affect the rationale, methodology or analysis. The authors of the article give thanks to O.Yu.Agapova, Senior Researcher of the Pulmonology Laboratory of the Research Medical and Dental Institute of the Federal State Budgetary Educational Institution of Higher Education "Moscow State Medical and Dental University named after A.I. Evdokimov" of the Ministry of Health of the Russian Federation for statistical processing of materials for the article., Спонсором исследования POPE-study является Ludwig Boltzmann Institute for COPD and Respiratory Epidemiology (Вена, Австрия). Этот исследовательский институт получил неограниченный исследовательский грант от Boehringer Ingelheim, который оказал частичную поддержку этому исследованию, но не влиял на обоснование, методологию или анализ. Авторы статьи выражают благодарность старшему научному сотруднику лаборатории пульмонологии Научно-исследовательского медико-стоматологического института Федерального государственного бюджетного образовательного учреждения высшего образования «Московский государственный медико-стоматологический университет имени А.И.Евдокимова» Министерства здравоохранения Российской Федерации, О.Ю.Агаповой за статистическую обработку материалов для статьи.

المصدر: PULMONOLOGIYA; Том 30, № 1 (2020); 42-52 ; Пульмонология; Том 30, № 1 (2020); 42-52 ; 2541-9617 ; 0869-0189 ; 10.18093/0869-0189-2020-30-1

مصطلحات موضوعية: клиническая практика, phenotypes, treatment, comorbid diseases, clinical practice, фенотипы, лечение, коморбидные заболевания

وصف الملف: application/pdf

Relation: https://journal.pulmonology.ru/pulm/article/view/1276/978; Global Initiative for Chronic Obstructive Lung Disease. 2020 Global Strategy for the Diagnosis, Management and Prevention of COPD. Available at: https://goldcopd.org/gold-reports/; Jones P.W. Health status and the spiral of decline. J. COPD. 2009. 6 (1): 59–63. DOI:10.1080/15412550802587943.; Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease Global Initiative for Chronic Obstructive Lung Disease. 2011 Report. Available at: http://www.goldcopd.org/; Han M.K., Agusti A., Calverley P.M. et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am. J. Respir. Crit. Care Med. 2010; 182 (5): 598–604. DOI:10.1164/rccm.200912-1843CC.; Koblizek V., Chlumsky J., Zindr V. et al. Chronic obstructive pulmonary disease: official diagnosis and treatment guidelines of the Czech Pneumological and Phthisiological Society; a novel phenotypic approach to COPD with patient-oriented care. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub. 2013; 157 (2): 189–201. DOI:10.5507/bp.2013.039.; Чучалин А.Г., Авдеев С.Н., Айсанов З.Р. и др. Российское респираторное общество. Федеральные клинические рекомендации по диагностике и лечению хронической обструктивной болезни легких. Пульмонология. 2014; (3): 15–54. DOI:10.18093/0869-0189-20140-3-15-54.; Zbozinkova Z., Barczyk A., Tkacova R. et al. POPE study: rationale and methodology of a study to phenotype patients with COPD in Central and Eastern Europe. Int. J. Chron. Obstruct. Pulmon. Dis. 2016; 11 (1): 611–622. DOI:10.2147/COPD.S88846.; Miravitlles M., Soler-Cataluña J.J., Calle M. et al. Spanish guideline for COPD (GesEPOC). Update 2014. Arch. Bronconeumol. 2014; 50 (Suppl. 1): 1–16. DOI:10.1016/S0300-2896(14)70070-5.; Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chronic. Dis. 1987; 40 (5): 373–383. DOI:10.1016/0021-9681(87)90171-8.; Miller M.R., Hankinson J., Brusasco V. et al. Standardisation of spirometry. Eur. Respir. J. 2005; 26 (2): 319–338. DOI:10.1183/09031936.05.00034805.; Pellegrino R., Viegi G., Brusasco V. et al. Interpretative strategies for lung function tests. Eur. Respir. J. 2005; 26 (5): 948–968. DOI:10.1183/09031936.05.00035205.; Roca J., Burgos F., Sunyer J. et al. References values for forced spirometry. Group of the European Community Respiratory Health Survey. Eur. Respir. J. 1998; 11 (6): 1354–1362. DOI:10.1183/09031936.98.11061354.; Diab N., Gershon A.S., Sin D.D. et al. Underdiagnosis and overdiagnosis of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2018; 198 (9): 1130–1139. DOI:10.1164/rccm.201804-0621CI.; Miravitlles M., Vogelmeier C., Roche N. et al. A review of national guidelines for management of COPD in Europe. Eur. Respir. J. 2016; 47 (2): 625–637. DOI:10.1183/13993003.01170-2015.; Burrows B., Hopkins J., Fletcher C.M. et al. The emphysematous and bronchial types of chronic airways obstruction: A clinicopathological study of patients in London and Chicago. Lancet. 1966; 287 (7442): 830–835. DOI:10.1016/s0140-6736(66)90181-4.; Cosio B.G., Soriano J.B., López-Campos J.L. et al. Distribution and outcomes of a phenotype-based approach to guide COPD management: results from the CHAIN cohort. PLoS One. 2016; (11): e0160770. DOI:10.1371/journal.pone.0160770.; Koblizek V., Milenkovic B., Barczyk A. et al. Phenotypes of COPD patients with a smoking history in Central and Eastern Europe: the POPE study. Eur. Respir. J. 2017; 49 (5): 1601446. DOI:10.1183/13993003.01446-2016.; Pasquale M.K., Sun S.X., Song F. et al. Impact of exacerbations on health care cost and resource utilization in chronic obstructive pulmonary disease patients with chronic bronchitis from a predominantly Medicare population. Int. J. Chron. Obstruct. Pulmon. Dis. 2012; 7: 757–764. DOI:10.2147/COPD.S36997.; Lindberg A., Sawalha S., Hedman L. et al. Subjects with COPD and productive cough have an increased risk for exacerbations and death. Respir. Med. 2015; 109 (1): 88–95. DOI:10.1016/j.rmed.2014.12.001.; Martinez F.J., Calverley P.M., Goehring U.M. et al. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentrer randomized controlled trial. Lancet. 2015; 385 (9971): 857–866. DOI:10.1016/S0140-6736(14)62410-7.; Wedzicha J.A., Singh D., Vestbo J. et al. Extrafine beclomethasone/formoterol in severe COPD patients with history of exacerbations. Respir. Med. 2014; 108 (8): 11531162. DOI:10.1016/j.rmed.2014.05.013.; Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. 2016 Update. Available at: https://ginasthma.org/wp-content/uploads/2016/04/GINA2016-main-report_tracked.pdf [Accessed: May 26, 2016].; Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of COPD. 2017 Report. Available at: http://goldcopd.org [Accessed: January 8, 2017].; Tudoric N., Koblizek V., Miravitlles M. et al. GOLD 2017 on the way to a phenotypic approach? Analysis from the phenotypes of COPD in Central and Eastern Europe (POPE) Cohort. Eur. Respir. J. 2017; 49 (4): 1602518. DOI:10.1183/13993003.02518-2016.; https://journal.pulmonology.ru/pulm/article/view/1276

الاتاحة: https://journal.pulmonology.ru/pulm/article/view/1276
https://doi.org/10.18093/0869-0189-2020-30-1-42-52

المؤلفون: N. M. Lazareva, O. P. Baranova, I. V. Kudryavtsev, N. A. Arsentieva, N. E. Liubimova, T. P. Ses’, M. M. Ilkovich, Areg A. Totolian, Н. М. Лазарева, О. П. Баранова, И. В. Кудрявцев, Н. А. Арсентьева, Н. Е. Любимова, Т. П. Сесь, М. М. Илькович, Арег А. Тотолян

المصدر: Medical Immunology (Russia); Том 22, № 5 (2020); 993-1002 ; Медицинская иммунология; Том 22, № 5 (2020); 993-1002 ; 2313-741X ; 1563-0625

مصطلحات موضوعية: плазма крови, cytokines, chemokines, growth factors, peripheral blood plasma, цитокины, хемокины, ростовые факторы

وصف الملف: application/pdf

Relation: https://www.mimmun.ru/mimmun/article/view/2064/1318; Баранова О.П., Кудрявцев И.В., Лазарева Н.М., Серебрякова М.К., Сесь Т.П., Илькович М.М., Тотолян Арег А. Цитотоксические Т-лимфоциты при хроническом течении саркоидоза // Российский иммунологический журнал, 2018. Т. 12 (21), № 4. С. 605-608.; Илькович М.М. Интерстициальные и орфанные заболевания легких. М.: ГЕОТАР-Медиа, 2016. 560 с.; Кудрявцев И.В., Борисов А.Г., Кробинец И.И., Савченко А.А., Серебрякова М.К., Тотолян А.А. Хемокиновые рецепторы на Т-хелперах различного уровня дифференцировки: основные субпопуляции // Медицинская иммунология, 2016. T. 18, № 3. С. 239-250. doi:10.15789/1563-0625-2016-3-239-250.; Кудрявцев И.В., Лазарева Н.М., Баранова О.П., Серебрякова М.К., Сесь Т.П., Илькович М.М., Тотолян Арег А. Особенности экспрессии CD57 цитотоксическими Т-лимфоцитами при саркоидозе // Российский иммунологический журнал, 2018. Т. 12 (21), № 3. С. 329-334.; Кудрявцев И.В., Лазарева Н.М., Баранова О.П., Головкин А.С., Исаков Д.В., Серебрякова М.К., Сесь Т.П., Илькович М.М., Тотолян Арег А. Экспрессия CD39 регуляторными Т-лимфоцитами при хроническом и остром саркоидозе // Медицинская иммунология, 2019. Т. 21, № 3. С. 467-478. doi:10.15789/1563-0625-2019-3-467-478.; Лазарева Н.М., Кудрявцев И.В., Баранова О.П., Серебрякова М.К., Сесь Т.П., Илькович М.М., Тотолян Арег А. Субпопуляционный состав цитотоксических Т-лимфоцитов периферической крови при саркоидозе // Российский иммунологический журнал, 2018. Т. 12 (21), № 3. С. 348-353.; Лазарева Н.М., Кудрявцев И.В., Баранова О.П., Серебрякова М.К., Сесь Т.П., Илькович М.М., Тотолян Арег А. Анализ субпопуляций В-лимфоцитов в периферической крови больных саркоидозом при разной степени активности заболевания // Медицинская иммунология, 2019. Т. 21, № 6. С. 1081-1098. doi:10.15789/1563-0625-2019-6-1081-1098.; Aksoy M.O., Yang Y., Ji R., Reddy P.J., Shahabuddin S., Litvin J., Rogers T.J., Kelsen S.G. CXCR3 surface expression in human airway epithelial cells: cell cycle dependence and effect on cell proliferation. Am. J. Physiol. Lung Cell Mol. Physiol., 2006, Vol. 290, no. 5, pp. 909-918.; Arger N.K., Ho M.E., Allen I.E., Benn B.S., Woodruff P.G., Koth L.L. CXCL9 and CXCL10 are differentially associated with systemic organ involvement and pulmonary disease severity in sarcoidosis. Respir. Med., 2020, Vol. 161, 105822. doi:10.1016/j.rmed.2019.105822.; d’Ambrosio D., Albanesi C., Lang R., Girolomoni G., Sinigaglia F. and Laudanna C. Quantitative differences in chemokine receptor engagement generate diversity in integrin-dependent lymphocyte adhesion. J. Immunol., 2002, Vol. 169, pp. 2303-2312.; Garcia-Lopez M.A., Sanchez-Madrid F., Rodriguez-Frade J.M., Mellado M., Acevedo A., Garcia M.I., Albar J.P., Martinez C., Marazuela M. CXCR3 chemokine receptor distribution in normal and inflamed tissues: expression on activated lymphocytes, endothelial cells, and dendritic cells. Lab. Invest., 2001, Vol. 81, pp. 409-418.; Greaves S.A., Atif S.M., Fontenot A.P. Adaptive immunity in pulmonary sarcoidosis and chronic beryllium disease. Front. Immunol., 2020, Vol. 11, 474. doi:10.3389/fimmu.2020.00474.; Groom J.R., Luster A.D. CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunol. Cell Biol., 2011, Vol. 89, no. 2, pp. 207-215.; Kobak S. Sarcoidosis: a rheumatologist’s perspective. Ther. Adv. Musculoskelet. Dis., 2015, Vol. 7, no. 5, pp. 196-205.; Miedema J.R., Kaiser Y., Broos C.E., Wijsenbeek M.S., Grunewald J., Kool M. Th17-lineage cells in pulmonary sarcoidosis and Löfgren’s syndrome: friend or foe? J. Autoimmun., 2018, Vol. 87, pp. 82-96.; Muehlinghaus G., Cigliano L., Huehn S., Peddinghaus A., Leyendeckers H., Hauser A.E. Regulation of CXCR3 and CXCR4 expression during terminal differentiation of memory B cells into plasma cells. Blood, 2005, Vol. 105, pp. 3965-3971.; Nguyen C.T.H., Kambe N., Ueda-Hayakawa I., Kishimoto I., Ly N.T.M., Mizuno K., Okamoto H. TARC expression in the circulation and cutaneous granulomas correlates with disease severity and indicates Th2-mediated progression in patients with sarcoidosis. Allergol. Int., 2018, Vol. 67, no. 4, pp. 487-495.; Nishioka Y., Manabe K., Kishi J., Wang W., Inayama M., Azuma M., Sone S. CXCL9 and 11 in patients with pulmonary sarcoidosis: a role of alveolar macrophages. Clin. Exp. Immunol., 2007, Vol. 149, pp. 317-326.; Nureki S., Miyazaki E., Ando M., Ueno T., Fukami T., Kumamoto T., Sugisaki K., Tsuda T. Circulating levels of both Th1 and Th2 chemokines are elevated in patients with sarcoidosis. Respir. Med., 2008, Vol. 102, no. 2, pp. 239-247.; Piotrowski W.J., Kiszałkiewicz J., Górski P., Antczak A., Górski W., Pastuszak-Lewandoska D., MigdalskaSęk M., Domańska-Senderowska D., Nawrot E., Czarnecka K.H., Kurmanowska Z., Brzeziańska-Lasota E. Immunoexpression of TGF-β/Smad and VEGF-A proteins in serum and BAL fluid of sarcoidosis patients. BMC Immunol., 2015, Vol. 16, 58. doi:10.1186/s12865-015-0123-y.; Ragusa F. Sarcoidosis and Th1 chemokines. Clin Ter., 2015, Vol. 166, no. 1, pp. 72-76.; Sakthivel P., Bruder D. Mechanism of granuloma formation in sarcoidosis. Curr. Opin. Hematol., 2017, Vol. 24, no. 1, pp. 59-65.; Strieter R.M., Burdick M.D., Gomperts B.N., Belperio J.A., Keane M.P. CXC chemokines in angiogenesis. Cytokine Growth Factor Rev., 2005, Vol. 16, no. 6, pp. 593-609.; Su R., Nguyen M.L., Agarwal M.R., Kirby C., Nguyen C.P., Ramstein J., Darnell E.P., Gomez A.D., Ho M., Woodruff P.G., Koth L.L. Interferon-inducible chemokines reflect severity and progression in sarcoidosis. Respir. Res., 2013, Vol. 14, 121. doi:10.1186/1465-9921-14-121.; Torraca V., Cui C., Boland R., Bebelman J.P., van der Sar A.M., Smit M.J., Siderius M., Spaink H.P., Meijer A.H. The CXCR3-CXCL11 signaling axis mediates macrophage recruitment and dissemination of mycobacterial infection. DMM, 2015, Vol. 8, no. 3, pp. 253-269.; Tuleta I., Biener L., Pizarro C., Nickenig G., Skowasch D. Proangiogenic and profibrotic markers in pulmonary sarcoidosis. Adv. Exp. Med. Biol., 2018, Vol. 1114, pp. 57-66.; Ziora D., Jastrzębski D., Adamek M., Czuba Z., Kozielski J.J., Grzanka A., Kasperska-Zajac A. Circulating concentration of markers of angiogenic activity in patients with sarcoidosis and idiopathic pulmonary fibrosis. BMC Pulm Med., Vol. 2015, Vol. 15, 113. doi:10.1186/s12890-015-0110-3.; https://www.mimmun.ru/mimmun/article/view/2064

الاتاحة: https://www.mimmun.ru/mimmun/article/view/2064
https://doi.org/10.15789/1563-0625-FOC-2064

المؤلفون: M. M. Il'kovich, М. М. Илькович

المصدر: PULMONOLOGIYA; Том 26, № 6 (2016); 770-774 ; Пульмонология; Том 26, № 6 (2016); 770-774 ; 2541-9617 ; 0869-0189 ; 10.18093/0869-0189-2016-26-6

وصف الملف: application/pdf

Relation: https://journal.pulmonology.ru/pulm/article/view/803/683; https://journal.pulmonology.ru/pulm/article/view/803

الاتاحة: https://journal.pulmonology.ru/pulm/article/view/803
https://doi.org/10.18093/0869-0189-2016-26-6-770-774

المؤلفون: Anna S. Ulitina, Lubov’ N. Novikova, Yuliya M. Il'kovich, Olga P. Baranova, Tat'yana V. Makarova, Evgeniya V. Volkova, Sofiya N. Pchelina, Mikhail M. Il'kovich, Mikhail V. Dubina, А. С. Улитина, Л. Н. Новикова, Ю. М. Илькович, О. П. Баранова, Т. В. Макарова, Е. В. Волкова, С. Н. Пчелина, М. М. Илькович, М. В. Дубина

المصدر: PULMONOLOGIYA; Том 27, № 3 (2017); 346-356 ; Пульмонология; Том 27, № 3 (2017); 346-356 ; 2541-9617 ; 0869-0189 ; 10.18093/0869-0189-2017-27-3

مصطلحات موضوعية: однонуклеотидный полиморфизм, idiopathic interstitial pneumonias, sarcoidosis, genes, single nucleotide polymorphism, идиопатическая интерстициальная пневмония, саркоидоз, гены

وصف الملف: application/pdf

Relation: https://journal.pulmonology.ru/pulm/article/view/876/741; Илькович М.М., ред. Интерстициальные и орфанные заболевания легких. М.: ГЭОТАР-Медиа; 2016.; Kreuter M., Herth F.J., Wacker M. et al. Exploring Clinical and Epidemiological Characteristics of Interstitial Lung Diseases: Rationale, Aims, and Design of a Nationwide Prospective Registry –The EXCITING-ILD Registry. Biomed. Res. Int. 2015; 2015: 123876. DOI:10.1155/2015/123876.; Bajwa A., Osmanzada D., Osmanzada S. et al. Epidemiology of uveitis in the mid-Atlantic United States. Clin. Ophthalmol. 2015; (9): 889–901. DOI:10.2147/OPTH.S80972.; Mirsaeidi M., Machado R.F., Schraufnagel D. et al. Racial difference in sarcoidosis mortality in the United States. Chest. 2015; 147 (2): 438–449. DOI:10.1378/chest.14-1120.; Илькович М.М., Новикова Л.Н., Сперанская А.А. Идиопатический фиброзирующий альвеолит: современные представления. Consilium Medicum. 2009; (11): 24–29.; Чучалин А.Г., Визель А.А, Илькович М.М. и др. Диагностика и лечение саркоидоза: резюме федеральных согласительных клинических рекомендаций. Часть I. Классификация, этиопатогенез, клиника. Вестник современной клинической медицины. 2014; 7 (4): 62–70.; Inoue I., Nakajima T., Williams C.S. et al. A nucleotide substitution in the promoter of human angiotensinogen is associated with essential hypertension and affects basal transcription in vitro. J. Clin. Invest. 1997; 99 (7): 1786–1797. DOI:10.1172/JCI119343.; Shu X.O., Gao Y.T., Cai Q. et al. Genetic polymorphisms in the TGF-beta 1 gene and breast cancer survival: a report from the Shanghai Breast Cancer Study. Cancer Res. 2004; 64 (3): 836–839.; van Meurs J.B., Schuit S.C., Weel A.E. et al. Association of 5' estrogen receptor alpha gene polymorphisms with bone mineral density, vertebral bone area and fracture risk. Hum. Mol. Genet. 2003; 12 (14): 1745–1754.; Horst-Sikorska W., Kalak R., Wawrzyniak A. et al. Association analysis of the polymorphisms of the VDR gene with bone mineral density and the occurrence of fractures. J. Bone Miner. Metab. 2007; 25 (5): 310–319. DOI:10.1007/s00774-007-0769-5.; Hofmann S., Fischer A., Nothnagel M. et al. Genome-wide association analysis reveals 12q13.3-q14.1 as new risk locus for sarcoidosis. Eur. Respir. J. 2013; 41 (4): 888–900. DOI:10.1183/09031936.00033812.; Fingerlin T.E., Zhang W., Yang I.V. et al. Genome-wide imputation study identifies novel HLA locus for pulmonary fibrosis and potential role for auto-immunity in fibrotic idiopathic interstitial pneumonia. BMC Genet. 2016; 17 (1): 74. DOI:10.1186/s12863-016-0377-2.; Fischer A., Grunewald J., Spagnolo P. et al. Genetics of sarcoidosis. Semin. Respir. Crit. Care Med. 2014; 35 (3): 296–306. DOI:10.1055/s-0034-1376860.; Zhou W., Wang Y. Candidate genes of idiopathic pulmonary fibrosis: current evidence and research. Appl. Clin. Genet. 2016; (9): 5–13. DOI:10.2147/TACG.S61999.; Molina-Molina M., Xaubet A., Li X. et al. Angiotensinogen gene G-6A polymorphism influences idiopathic pulmonary fibrosis disease progression. Eur. Respir. J. 2008; 32 (4): 1004–1008. DOI:10.1183/09031936.00015808.; Arja C., Ravuri R.R., Pulamaghatta V.N. et al. Genetic determinants of chronic obstructive pulmonary disease in South Indian male smokers. PLoS One. 2014; 9 (2): e89957. DOI:10.1371/journal.pone.0089957.; Yang Y.C., Zhang N., Van Crombruggen K. et al. Transforming growth factor-beta1 in inflammatory airway disease: a key for understanding inflammation and remodeling. Allergy. 2012; 67 (10): 1193–1202. DOI:10.1111/j.1398-9995.2012.02880.x.; Shah R., Hurley C.K., Posch P.E. A molecular mechanism for the differential regulation of TGF-beta1 expression due to the common SNP -509C-T (c. -1347C > T). Hum. Genet. 2006; 120 (4): 461–469. DOI:10.1007/s00439-006-0194-1.; Jakimiuk A., Nowicka M., Bogusiewicz M. et al. Prevalence of estrogen receptor alpha PvuII and XbaI polymorphism in population of Polish postmenopausal women. Folia. Histochem. Cytobiol. 2007; 45 (4): 331–338.; Koppelman G.H., Sayers I. Evidence of a genetic contribution to lung function decline in asthma. J. Allergy Clin. Immunol. 2011; 128 (3): 479–484. DOI:10.1016/j.jaci.2011.05.036.; Uhal B.D., Kim J.K., Li X., Molina-Molina M. Angiotensin-TGF-beta 1 crosstalk in human idiopathic pulmonary fibrosis: autocrine mechanisms in myofibroblasts and macrophages. Curr. Pharm. Des. 2007; 13 (12): 1247–1256.; Daing A., Singh S.V., Saimbi C.S. et al. Single nucleotide polymorphisms at interleukin (IL)-1 b + 3954 and vitamin D receptor (VDR) TaqI in chronic periodontitis patients: A pilot study in North Indian population. J. Int. Clin. Dent. Res. Organ. 2015; 7: 18–23. DOI:10.4103/2231-0754.153490.; Perna L., Butterbach K., Haug U. et al. Vitamin D receptor genotype rs731236 (Taq1) and breast cancer prognosis. Cancer Epidemiol. Biomarkers Prev. 2013; 22 (3): 437–442. DOI:10.1158/1055-9965.EPI-12-0970-T.; Barna B.P., Culver D.A., Kanchwala A. et al. Alveolar macrophage cathelicidin deficiency in severe sarcoidosis. J. Innate Immun. 2012; 4 (5–6): 569–578. DOI:10.1159/000339149.; Hewison M. Vitamin D and the intracrinology of innate immunity. Mol. Cell Endocrinol. 2010; 321 (2): 103–111. DOI:10.1016/j.mce.2010.02.013.; Rivera N.V., Ronninger M., Shchetynsky K. et al. High-density genetic mapping identifies new susceptibility variants in sarcoidosis phenotypes and shows genomic-driven phenotypic differences. Am. J. Respir. Crit. Care Med. 2016; 193 (9): 1008–1022. DOI:10.1164/rccm.201507-1372OC.; https://journal.pulmonology.ru/pulm/article/view/876

الاتاحة: https://journal.pulmonology.ru/pulm/article/view/876
https://doi.org/10.18093/0869-0189-2017-27-3-346-356

المؤلفون: A. G. Chuchalin, S. N. Avdeev, Z. R. Aisanov, A. S. Belevskiy, S. A. Demura, M. M. Il'kovich, E. A. Kogan, M. V. Samsonova, A. A. Speranskaya, I. E. Tyurin, A. L. Chernyaev, B. A. Chernyak, A. V. Chernyak, E. I. Shmelev, А. Г. Чучалин, С. Н. Авдеев, З. Р. Айсанов, А. С. Белевский, С. А. Демура, М. М. Илькович, Е. А. Коган, М. В. Самсонова, А. А. Сперанская, И. Е. Тюрин, А. Л. Черняев, Б. А. Черняк, А. В. Черняк, Е. И. Шмелев

المصدر: PULMONOLOGIYA; Том 26, № 4 (2016); 399-419 ; Пульмонология; Том 26, № 4 (2016); 399-419 ; 2541-9617 ; 0869-0189 ; 10.18093/0869-0189-2017-21-8

مصطلحات موضوعية: идиопатический легочный фиброз, non-specific interstitial pneumonia, idiopathic pulmonary fibrosis, неспецифическая интерстициальная пневмония

وصف الملف: application/pdf

Relation: https://journal.pulmonology.ru/pulm/article/view/741/641; Raghu G., Collard H.R., Egan J.J. et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis; evidence-based guidelines for diagnosis and management. Am. J. Respir. Crit. Care Med. 2011; 183: 788–824.; Raghu G., Rochwerg B., Zhang Y. et al. An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis: executive summary an update of the 2011 clinical practice guideline. Am. J. Respir. Crit. Care Med. 2015; 192: e3–e19.; Travis W.D., Costabe U., Hansell D.M.et al. An official American Thoracic Society / European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am. J. Respir. Crit. Care Med. 2013; 188: 733–748.; Ryu J.H., Moua T., Daniels C.E. et al. Idiopathic pulmonary fibrosis: evolving concepts. Mayo. Clin. Proc. 2014; 89: 1130–1142.; Taskar V.S., Coultas D.B. Is idiopathic pulmonary fibrosis an environmental disease. Proc. Am. Thorac. Soc. 2006; 3: 293–298.; El-Serag H.B., Sonnenberg A. Comorbid occurrence of laryngeal or pulmonary disease with esophagitis in United States military veterans. Gastroenterology. 1997; 113: 755–760.; Lee J.S., Song J.W., Wolters P.J. et al. Bronchoalveolar lavage pepsin in acute exacerbation of idiopathic pulmonary fibrosis. Eur. Respir. J. 2012; 39: 352–358.; Garcıa-Sancho Figueroa M.C., Carrillo G., Perez-Padilla R. et al. Risk factors for idiopathic pulmonary fibrosis in a Mexican population. A case-control study. Respir. Med. 2010; 104: 305–309.; Wolters P.J., Collard H.R., Jones K.D. Pathogenesis of idiopathic pulmonary fibrosis. Ann. Rev. Pathol. 2014; 9: 157–179.; Hodgson U., Pulkkinen V., Dixon M. et al. ELMOD2 is a candidate gene for familial idiopathic pulmonary fibrosis. Am. J. Hum. Genet. 2006; 79: 149–154.; Raghu G., Weycker D., Edelsberg J. et al. Incidence and prevalence of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2006; 174: 810–816.; Coultas D.B., Zumwalt R.E., Black W.C., Sobonya R.E. The epidemiology of interstitial lung diseases. Am. J. Respir. Crit. Care Med. 1994; 150: 967–972.; Nalysnyk L., Cid-Ruzafa J., Rotella P. et al. Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature. Eur. Respir. Rev. 2012; 21: 355–361.; Richeldi L., Rubin A.S., Avdeev S. et al. Idiopathic pulmonary fibrosis in BRIC countries: the cases of Brazil, Russia, India, and China. BMC Med. 2015; 13: 237.; Johnston I.D.A., Prescott R.J., Chalmers J.C. et al. British Thoracic Society study of cryptogenic fibrosing alveolitis: current presentation and initial management. Thorax. 1997; 52: 38–44.; du Bois R.M., Wells A.U. Cryptogenic fibrosing alveolitis/idiopathic pulmonary fibrosis. Eur. Respir. J. 2001; 18 (Suppl. 32): 43s–55s.; Piirila P., Sovijarvi A.R.A. Crackles: recording, analysis and clinical significance. Eur. Respir. J. 1995; 8: 2139–2148.; Flaherty K.R., King T.E. Jr, Raghu G. et al. Idiopathic interstitial pneumonia: what is the effect of a ultidisciplinary approach to diagnosis? Am. J. Respir. Crit. Care Med. 2004; 170: 904–910.; Monaghan H., Wells A.U., Colby T.V. et al. Prognostic implications of histologic patterns in multiple surgical lung biopsies from patients with idiopathic interstitial pneumonias. Chest. 2004; 125: 522–526.; Flaherty K.R., Travis W.D., Colby T.V. et al. Histopathologic variability in usual and nonspecific interstitial pneumonias. Am. J. Respir. Crit. Care Med. 2001; 164: 1722–1727.; Miller J.D., Urschel J.D., Cox G. et al. A randomized, controlled trial comparing thoracoscopy and limited thoracotomy for lung biopsy in interstitial lung disease. Ann. Thorac. Surg. 2000; 70: 1647–1650.; Carnochan F.M., Walker W.S., Cameron E.W. Efficacy of video assisted thoracoscopic lung biopsy: an historical comparison with open lung biopsy. Thorax. 1994; 49: 361–363.; Leslie K.O., Gruden J.F., Parish J.M., Scholand M.B. Transbronchial biopsy interpretation in the patient with diffuse parenchymal lung disease. Arch. Pathol. Lab. Med. 2007; 131: 407–423.; Grenier P., Valeyre D., Cluzel P. et al. Chronic diffuse interstitial lung disease: diagnostic value of chest radiography and high-resolution CT. Radiology. 1991; 179: 123–132.; Hansell D.M., Bankier A.A., MacMahon H. et al. Fleischner Society: glossary of terms for thoracic imaging. Radiology. 2008; 246: 697–722.; Johkoh T., Sakai F., Noma S. et al. Honeycombing on CT: its definitions, pathologic correlation, and future directionof its diagnosis. Eur. J. Radiol. 2014; 83: 27–31.; Sverzellati N., Wells A.U., Tomassetti S. et al. Biopsy-proved idiopathic pulmonary fibrosis: spectrum of nondiagnostic thin-section CT diagnoses. Radiology. 2010; 254: 957–964.; Behr J., Kreuter M., Hoeper M.M. et al. Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry. Eur. Respir. J. 2015; 46: 186–196.; Wiggins J., Strickland B., Turner-Warwick M. Combined cryptogenic fibrosing alveolitis and emphysema: the value of high resolution computed tomography in assessment. Respir. Med. 1990. 84: 365–369.; Doherty M.J., Pearson M.G., O’Grady E.A. et al. Cryptogenic fibrosing alveolitis with preserved lung volumes. Thorax. 1997. 52: 998–1002.; Collard H.R., King T.E. Jr, Bartelson B.B. et al. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2003; 168: 538–542.; du Bois R.M., Weycker D., Albera C. et al. Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am. J. Respir. Crit. Care Med. 2011; 184: 1382–1389.; Nathan S.D., du Bois R.M., Albera C. et al. Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis. Respir. Med. 2015; 109: 914–922.; Nicholson A.G. Interstitial pneumonias. In: Cagle P.T., Fraire A.E., Tomashefski J.F. Jr., Farver C.F., eds. Dail and Hammar's Pulmonary Pathology. Springer Science + Business Media, LLC; 2008: 695–721.; Agarwal R., Jindal S.K. Acute exacerbation of idiopathic pulmonary fibrosis: a systematic review. Eur. J. Intern. Med. 2008; 19: 227–235.; Gross T.J., Hunninghake G.W. Idiopathic pulmonary fibrosis. N. Engl. J. Med. 2001; 345: 517–525.; King T.E., Tooze J.A., Schwarz M.I. et al. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am. J. Respir. Crit. Care Med. 2001; 164: 1171–1181.; Kim D.S., Collard H.R., King T.E. Classification and natural history of the idiopathic interstitial pneumonias. Proc. Am. Thorac. Soc. 2006; 3: 285–292.; Collard H.R., Ryerson C.J., Corte T.J. et al. Acute exacerbations of idiopathic pulmonary fibrosis. An International Working Group Report. Am. J. Respir. Crit. Care Med. 2016; 194: 265–275.; Akira M., Hamada H., Sakatani M. et al. CT findings during phase of accelerated deterioration in patients with idiopathic pulmonary fibrosis. Am. J. Roentgenol. 1997; 168: 79–83.; Ambrosini V., Cancellieri A., Chilosi M. et al. Acute exacerbation of idiopathic pulmonary fibrosis: report of a series. Eur. Respir. J. 2003; 22: 821–826.; Konishi K., Gibson K.F., Lindell K.O. et al. Gene expression profiles of acute exacerbations of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2009; 180: 167–175.; Kim D.S., Park J.H., Park B.K. et al. Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features. Eur. Respir. J. 2006; 27: 143–150.; Kondoh Y., Taniguchi H., Kitaichi M. et al. Acute exacerbation of interstitial pneumonia following surgical lung biopsy. Respir. Med. 2006; 100: 1753–1759.; Hiwatari N., Shimura S., Takishima T., Shirato K. Bronchoalveolar lavage as a possible cause of acute exacerbation in idiopathic pulmonary fibrosis patients. Tohoku J. Exp. Med. 1994; 174: 379–386.; Parambil J.G., Myers J.L., Ryu J.H. Histopathologic features and outcome of patients with acute exacerbation of idiopathic pulmonary fibrosis undergoing surgical lung biopsy. Chest. 2005; 128: 3310–3315.; Cottin V., Nunes H., Brillet P.Y. et al. Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur. Respir. J. 2005; 26: 586–593.; Stahel R.A., Gilks W.R., Lehmann H.P., Schenker T. Third International Workshop on Lung Tumor and Differentiation Antigens: overview of the results of the central data analysis. Int. J. Cancer. Suppl. 1994; 8: 6–26.; Kohno N., Kyoizumi S., Awaya Y. et al. New serum indicator of interstitial pneumonitis activity: sialylated carbohydrate antigen KL-6. Chest. 1989; 96: 68–73.; Авдеева О.Е., Лебедин Ю.С., Авдеев С.Н. и др. Гликозилированный муцин-антиген 3EG5 − сывороточный маркер активности и тяжести при интерстициальных заболеваниях легких. Пульмонология. 1998; 2: 22–27.; Greene K.E., King T.E. Jr, Kuroki Y. et al. Serum surfactant proteins-A and -D as biomarkers in idiopathic pulmonary fibrosis. Eur. Respir. J. 2002; 19: 439–446.; Shinoda H., Tasaka S., Fujishima S. et al. Elevated CC chemokine level in bronchoalveolar lavage fluid is predictive of a poor outcome of idiopathic pulmonary fibrosis. Respiration. 2009; 78: 285–292.; Leuchte H.H., Baumgartner R.A., Nounou M.E. et al. Brain natriuretic peptide is a prognostic parameter in chronic lung disease. Am. J. Respir. Crit. Care Med. 2006; 173: 744–750.; Rosas I.O., Richards T.J., Konishi K. et al. MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. PLoS Med. 2008; 5: e93.; Phelps D.S., Umstead T.M., Mejia M. et al. Increased surfactant protein-A levels in patients with newly diagnosed idiopathic pulmonary fibrosis. Chest. 2004; 125: 617–625.; McCormack F.X., King T.E. Jr, Bucher B.L. et al. Surfactant protein A predicts survival in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 1995; 152: 751–759.; Moeller A., Gilpin S.E., Ask K. et al. Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2009; 179: 588–594.; Davies H.R., Richeldi L., Walters E.H. Immunomodulatory agents for idiopathic pulmonary fibrosis. Cochrane Database Syst. Rev. 2003; (3): CD003134.; Richeldi L., Davies H.R., Ferrara G., Franco F. Corticosteroids for idiopathic pulmonary fibrosis. Cochrane Database Syst. Rev. 2003; (3): CD002880.; Gay S.E., Kazerooni E.A., Toews G.B. et al. Idiopathic pulmonary fibrosis: predicting response to therapy and survival. Am. J. Respir. Crit. Care Med. 1998; 157: 1063–1072.; Flaherty K.R., Toews G.B., Lynch J.P. III et al. Steroids in idiopathic pulmonary fibrosis: a prospective assessment of adverse reactions, response to therapy, and survival. Am. J. Med. 2001; 110: 278–282.; Demedts M., Behr J., Buhl R. et al. IFIGENIA Study Group. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2005; 353 (21): 2229–2242.; Oldham J.M., Ma S.-F., Martinez F.J. et al. TOLLIP, MUC5B, and the response to N-acetylcysteine among individuals with idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2015; 192: 1475–1482.; Raghu G., Anstrom K.J., King T.E. Jr et al. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N. Engl. J. Med. 2012; 366: 1968–1977.; Richeldi L., Costabel U., Selman M. et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2011; 365: 1079–1087.; Richeldi L., du Bois R.M., Raghu G. et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2014; 370: 2071–2082.; Oku H., Shimizu T., Kawabata T. et al. Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. Eur. J. Pharmacol. 2008; 590: 400–408.; King T.E. Jr, Bradford W.Z., Castro-Bernardini S. et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 2014; 370: 2083–2092.; Douglas W.W., Ryu J.H., Schroeder D.R. Idiopathic pulmonary fibrosis: Impact of oxygen and colchicine, prednisone, or no therapy on survival. Am. J. Respir. Crit. Care Med. 2000; 161: 1172–1178.; Morrison D.A., Stovall J.R. Increased exercise capacity in hypoxemic patients after long-term oxygen therapy. Chest. 1992; 102: 542–550.; Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann. Intern. Med. 1980; 93: 391–398.; Long-term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema: report of the Medical Research Council Working Party. Lancet. 1981; 1: 681–686.; Mason D.P., Brizzio M.E., Alster J.M. et al. Lung transplantation for idiopathic pulmonary fibrosis. Ann. Thorac. Surg. 2007; 84: 1121–1128.; Keating D., Levvey B., Kotsimbos T. et al. Lung transplantation in pulmonary fibrosis: challenging early outcomes counterbalanced by surprisingly good outcomes beyond 15 years. Transplant. Proc. 2009; 41: 289–291.; Thabut G., Mal H., Castier Y. et al. Survival benefit of lung transplantation for patients with idiopathic pulmonary fibrosis. J. Thorac. Cardiovasc. Surg. 2003; 126: 469–475.; Egan J.J., Martinez F.J., Wells A.U., Williams T. Lung function estimates in idiopathic pulmonary fibrosis: the potential for a simple classification. Thorax. 2005; 60: 270–273.; Thabut G., Christie J.D., Ravaud P. et al. Survival after bilateral versus single-lung transplantation for idiopathic pulmonary fibrosis. Ann. Intern. Med. 2009; 151: 767–774.; Stern J.B., Mal H., Groussard O. et al. Prognosis of patients with advanced idiopathic pulmonary fibrosis requiring mechanical ventilation for acute respiratory failure. Chest. 2001; 120: 213–219.; Al-Hameed F.M., Sharma S. Outcome of patients admitted to the intensive care unit for acute exacerbation of idiopathic pulmonary fibrosis. Can. Respir. J. 2004; 11: 117–122.; Mollica C., Paone G., Conti V. et al. Mechanical ventilation in patients with end-stage idiopathic pulmonary fibrosis. Respiration. 2010; 79: 209–215.; Mallick S. Outcome of patients with idiopathic pulmonary fibrosis (IPF) ventilated in intensive care unit. Respir. Med. 2008; 102: 1355–1359.; Holland A.E., Hill C.J., Conron M. et al. Short term improvement in exercise capacity and symptoms following exercise training in interstitial lung disease. Thorax. 2008; 63: 549–554.; Nishiyama O., Kondoh Y., Kimura T. et al. Effects of pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis. Respirology. 2008; 13: 394–399.; Ferreira A., Garvey C., Connors G.L. et al. Pulmonary rehabilitation in interstitial lung disease: benefits and predictors of response. Chest. 2009; 135: 442–447.; Jastrzebski D., Gumola A., Gawlik R., Kozielski J. Dyspnea and quality of life in patients with pulmonary fibrosis after six weeks of respiratory rehabilitation. J. Physiol. Pharmacol. 2006; 57: 139–148.; Naji N.A., Connor M.C., Donnelly S.C., McDonnell T.J. Effectiveness of pulmonary rehabilitation in restrictive lung disease. J. Cardiopulm. Rehabil. 2006; 26: 237–243.; Ghofrani H.A., Wiedemann R., Rose F. et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet. 2002; 360: 895–900.; Madden B.P., Allenby M., Loke T., Sheth A. A potential role for sildenafil in the management of pulmonary hypertension in patients with parenchymal lung disease. Vascul. Pharmacol. 2006; 44: 372–376.; Collard H.R., Anstrom K.J., Schwarz M.I., Zisman D.A. Sildenafil improves walk distance in idiopathic pulmonary fibrosis. Chest. 2007; 131: 897–899.; Olschewski H., Ghofrani H.A., Walmrath D. et al. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am. J. Respir. Crit. Care Med. 1999; 160: 600–607.; Minai O.A., Sahoo D., Chapman J.T., Mehta A.C. Vaso-active therapy can improve 6-min walk distance in patients with pulmonary hypertension and fibrotic interstitial lung disease. Respir. Med. 2008; 102: 1015–1020.; Raghu G., Yang S.T., Spada C. et al. Sole treatment of acid gastroesophageal reflux in idiopathic pulmonary fibrosis: a case series. Chest. 2006; 129: 794–800.; Linden P.A., Gilbert R.J., Yeap B.Y. et al. Laparoscopic fundoplication in patients with end-stage lung disease awaiting transplantation. J. Thorac. Cardiovasc. Surg. 2006; 131: 438–446.; Lee J.S., Ryu J.H., Elicker B.M. et al. Gastroesophageal reflux therapy is associated with longer survival in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2011; 184: 1390–1394.; Savarino E., Bazzica M., Zentilin P. et al. Gastroesophageal reflux and pulmonary fibrosis in scleroderma: a study using pH-impedance monitoring. Am. J. Respir. Crit. Care Med. 2009; 179: 408–413.; Gulmez S.E., Holm A., Frederiksen H. et al. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Arch. Intern. Med. 2007; 167: 950–955.; Yang Y.X., Lewis J.D., Epstein S. et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006; 296: 2947–2953.; King T.E. Jr, Safrin S., Starko K.M. et al. Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis. Chest. 2005; 127: 171–177.; Zappala C.J., Latsi P.I., Nicholson A.G. et al. Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis. Eur. Respir. J. 2010; 35: 830–836.; Raghu G., Brown K.K., Bradford W.Z. et al. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 2004; 350: 125–133.; Azuma A., Nukiwa T., Tsuboi E. et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2005; 171: 1040–1047.; ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am. J. Respir. Crit. Care Med. 2002; 166: 111–117.; https://journal.pulmonology.ru/pulm/article/view/741

الاتاحة: https://journal.pulmonology.ru/pulm/article/view/741
https://doi.org/10.18093/0869-0189-2016-26-4-399-419

المؤلفون: T. E. Gembitskaya, A. G. Chermenskiy, M. M. Il'kovich, S. Camprubi, Т. Е. Гембицкая, А. Г. Черменский, М. М. Илькович, С. Цампруби

المصدر: PULMONOLOGIYA; № 6 (2014); 115-121 ; Пульмонология; № 6 (2014); 115-121 ; 2541-9617 ; 0869-0189 ; 10.18093/0869-0189-2017-0-3

مصطلحات موضوعية: дефицит α1-антитрипсина, alpha-1-antitrypsin deficiency

وصف الملف: application/pdf

Relation: https://journal.pulmonology.ru/pulm/article/view/501/485; The definition of emphysema. Report of a National Heart, Lung, and Blood Institute, Division of Lung Diseases workshop. Am. Rev. Respir. Dis. 1985; 132 (1): 182–185.; Laurell C.-B., Eriksson S. The electrophoretic alpha-1globulin pattern of serum in alpha-1-antitrypsin deficiency Scand. J. Clin. Lab. Invest. 1963; 15 (2): 132–140. DOI:10.1080/00365516309051324.; Ивчик Т.В. О генетике эмфиземы легких. Пульмонология. 2011; 4: 97–108.; Видаль Р., Бланко И., Касас Ф. и др. Рекомендации по диагностике и ведению больных с дефицитом α1-антитрипсина Испанского общества пульмонологии и торакальной хирургии (SEPAR). Пульмонология. 2008; 1: 14–28.; Овчаренко С.И., Сон Е.А. Влияние недостаточности α1-антитрипсина на поражение легких. Пульмонология. 2011; 5: 79–86.; Brebner J.A.; Stockley R.A. Recent advances in alpha-1antitrypsin deficiency related lung disease. Exp. Rev. Respir. Med. 2013; 7 (3): 213-230. DOI:10.1586/ers.13.20.; Sinden N.J., Stockley R.A. Proteinase 3 activity in sputum from subjects with alpha-1-antitrypsin deficiency and COPD. Eur. Respir. J. 2013; 41 (5): 1042–1050. DOI:10.1183/09031936.00089712.; Churg A., Zhou S., Wright J.L. Series 'matrix metalloproteinases in lung health and disease': matrix metalloproteinases in COPD. Eur. Respir. J. 2012; 39 (1): 197–209.; Blanco I., De Serres F.J., Fernandez-Bustillo E. et al. Deficit de alfa-1-antitripsina en España (variantes deficientes PiS y PiZ): prevalencia estimada y numero de sujetos deficientes calculados para cada fenotipo. Med. Clin. (Barc.) 2004; 123: 761–765.; Blanco I., de Serres F.J., Fernandez-Bustillo E. et al. Estimates of the prevalence of alpha-1-antitrypsin deficiency Pi*S and Pi*Z alleles and the numbers at risk in European countries. Eur. Respir. J. 2006; 27: 77–84.; Гембицкая Т.Е. Первичная эмфизема легких, связанная с дефицитом альфа-1-антитрипсина. Клиническая медицина. 1984; 9: 86–91.; Miravitlles M., Herr C., Ferrarotti I. et al. Laboratory testing of individuals with severe α1-antitrypsin deficiency in three European centres. Eur. Respir. J. 2010; 35 (5): 960–968.; Bornhorst J.A., Greene C.M., Ashwood E.R., Grenache D.G. α1-antitrypsin phenotypes and associated serum protein concentrations in a large clinical population. Chest. 2013; 143 (4): 1000–1008.; Chapman K.R., Stockley R.A., Dawkins C. et al. Augmentation therapy for α1-antitrypsin deficiency: a meta-analysis. COPD. 2009; 6 (3): 177–184.; Flotte T.R., Trapnell B.C., Humphries M. Phase 2 clinical trial of a recombinant adeno-associated viral vector expressing α1-antitrypsin: interim results. Hum. Gene. Ther. 2011; 22 (10): 1239–1247. DOI:10.1089/hum.2011.053.; https://journal.pulmonology.ru/pulm/article/view/501

الاتاحة: https://journal.pulmonology.ru/pulm/article/view/501
https://doi.org/10.18093/0869-0189-2014-0-6-115-121

المؤلفون: E. I. Shmelev, A. F. Abubikirov, N. M. Shmeleva, M. M. Ilkovich, N. A. Kuzubova, Е. И. Шмелев, А. Ф. Абубикиров, Н. М. Шмелева, М. М. Илькович, Н. А. Кузубова

المصدر: PULMONOLOGIYA; № 4 (2011); 80-86 ; Пульмонология; № 4 (2011); 80-86 ; 2541-9617 ; 0869-0189 ; 10.18093/0869-0189-2011-0-4

مصطلحات موضوعية: эффективность и безопасность, inhaled corticosteroids, basic therapy, BeclospirR, efficacy, safety, ингаляционные глюкокортикостероиды, базисная терапия, БеклоспирR

Relation: Чучалин А.Г. (ред.). Глобальная стратегия лечения и профилактики бронхиальной астмы (пересмотр 2007 г.). М.: Атмосфера; 2008.; Шмелев Е.И. Различия в диагностике и лечении бронхиальной астмы и хронической обструктивной болезни легких. Consilium medicum, 2002; 4 (9): 492–497.; Montuschi P., Pagliari G., Fuso L. Pharmacotherapy of asthma: Regular treatment or on demand? Ther. Adv. Resp. Dis. 2009; 3 (4):175–191.; Kelly H.W. Comparison of Inhaled Corticosteroids: an update. Ann. Pharmacother. 2009; 43 (3): 519–527.; https://journal.pulmonology.ru/pulm/article/view/364

الاتاحة: https://journal.pulmonology.ru/pulm/article/view/364
https://doi.org/10.18093/0869-0189-2011-0-4-80-86

المؤلفون: С. Н. Авдеев, М. М. Илькович, И. В. Лещенко, А. Ю. Петухова, А. В. Жестков, И. Д. Пелевина, Т. А. Корнилова, Т. В. Рубаник, А. В. Будневский, Е. П. Карпухина, Е. В. Гер, М. Ю. Цапаева, Л. К. Копейкина, Е. П. Кашанская, Е. А. Оськина, Н. Ю. Шварева, Е. Н. Бачинская

المصدر: PULMONOLOGIYA; № 6 (2010); 51-59 ; Пульмонология; № 6 (2010); 51-59 ; 2541-9617 ; 0869-0189 ; 10.18093/0869-0189-2010-0-6

مصطلحات موضوعية: ранние стадии, длительно действующие β2-агонисты, формотерол

وصف الملف: application/pdf

Relation: https://journal.pulmonology.ru/pulm/article/view/1717/1133; Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI / WHO workshop report. Last updated 2009. www.goldcopd.org; Celli B.R., MacNee W. ATS / ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS / ERS position paper. Eur. Respir. J. 2004; 23: 932-946; Buist A.S., McBurnie M.A., Vollmer W.M. et al. International variation in the prevalence of COPD (the BOLD Study): a populationbased prevalence study. Lancet 2007; 370: 741-750; Mannino D.M., Homa D.M., Akinbami L.J. et al. Chronic obstructive pulmonary disease surveillance - United States, 1971-2000. Morb. Mortal. Wkly Rep. Surveill. Summ. 2002; 51: 1-16; Richter K., Stenglein S., Mucke M. et al. Onset and duration of action of formoterol and tiotropium in patients with moderate to severe COPD. Respiration 2006; 73: 414-419; Dahl R., Greefhorst L.A.P.M., Nowak D. et al. Inhaled for� moterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2001; 164: 778-784; Rossi A., Kristufek P., Levine B.E. et al. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow�release theophylline in the treatment of COPD. Chest 2002; 121: 1058-1069; Steiropoulos P., Tzouvelekis A., Bouros D. Formoterol in the management of chronic obstructive pulmonary disease. Int. J. Chron. Obstruct. Pulmon. Dis. 2008; 3: 205-215; Aalbers R., Ayres J., Backer V. et al. Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3 month trial. Eur. Respir. J. 2002; 19: 936-943; Campbell M., Eliraz A., Johansson G. et al. Formoterol for maintenance and asneeded treatment of chronic obstructive pulmonary disease. Respir. Med. 2005; 99: 1511-1520; Wadbo M., Lofdahl C.G., Larsson K. et al. Effects of formoterol and ipratropium bromide in COPD: a 3-month placebocontrolled study. Eur. Respir. J. 2002; 20: 1138-1146; Jenkins C.R., Jones.PW., Calverley P.M.A. et al. Efficacy of salmeterol / fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebocontrolled TORCH study. Respir. Res. 2009; 10: 59 doi:10.1186/1465-9921-10-59; Чучалин А.Г., Авдеев С.Н., Илькович М.М. и др. Открытое наблюдательное исследование эффективности и при� верженности терапии препаратом Форадил Аэролайзер у пациентов с ХОБЛ. Атмосфера. Пульмонология и Ал� лергология 2010; 1: 25-30; Enright P.L., Sherrill D.L. Reference equations for the six� minute walk in healthy adults. Am. J. Respir. Crit. Care Med. 1998; 158: 1384-1387; Kind P. The EuroQoL instrument: an index of health�relat� ed quality of life. Chapter 22. In: Spilker B. (ed.) Quality of life and pharmacoeconomics in clinical trials. 2nd ed. Philadelphia, Lippincott�Raven Publishers; 1996: 191-201; Ruttenvan Mölken M.P., Oostenbrink J.B., Tashkin D.P. et al. Does quality of life of COPD patients as measured by the generic EuroQol five�dimension questionnaire differen� tiate between COPD severity stages? Chest 2006; 130: 1117-1128; Palmquist M., Persson G., Lazer L. et al. Inhaled dry powder formoterol and salmererol in asthmatic patients: onset of action, duration of effect and potency. Eur. Respir. J. 1997; 10: 2484-2489; Benhamou D., Cuvelier A., Muir J.F. et al. Rapid onset of bronchodilation in COPD: a placebo�controlled study com� paring formoterol (Foradil Aerolizer) with salbutamol (Ventodisk). Respir. Med. 2001; 95: 817-821; FitzGerald J.M., Chapman K.R., Della Cioppa G. et al. Sustained bronchoprotection, bronchodilatation, and symptom control during regular formoterol use in asthma of moderate or greater severity. The Canadian FO / OD1 Study Group. J. Allergy Clin. Immunol. 1999; 103: 427-435; Bensch G., Lapidus R.J., Levine B.E. et al. A randomized, 12- week, double-blind, placebo-controlled study comparing formoterol dry powder inhaler with albuterol metered-dose inhaler. Ann. Allergy Asthma Immunol. 2001; 86: 19-27; Qaseem A., Snow V., Shekelle P. et al., for the Clinical Efficacy Assessment Subcommittee of the American College of Physicians. Diagnosis and management of stable chronic obstructive pulmonary disease: A clinical practice guideline from the American College of Physicians. Ann. Intern. Med. 2007; 147: 633-638; Beaucage F., Frémault A., Janssens W. et al. FEV1 decline in COPD patients according to severity stages. Am. J. Respir. Crit. Care Med. 2008; 177: A401; PintoPlata V.M., CelliCruz R.A., Vassaux C. et al. Dif� ferences in cardiopulmonary exercise test results by American Thoracic Society / European Respiratory Society - Global Initiative for chronic obstructive lung disease stage categories and gender. Chest 2007; 132: 1204-1211; Pitta F., Troosters T., Spruit M.A. et al. Characteristics of physical activities in daily life in chronic obstructive pul� monary disease. Am. J. Respir. Crit. Care Med. 2005; 171: 972-977; O'Reilly J.F., Williams A.E., Holt K., Rice L. Defining COPD exacerbations: impact on estimation of incidence and burden in primary care. Prim. Care Respir. J. 2006; 15: 346-353; Hole D.J., Watt G.C., DaveySmith G. et al. Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study. Br. Med. J. 1996; 313: 711-715; Decramer M., Rennard S., Troosters T. et al. COPD as a lung disease with systemic consequences - clinical impact, mechanisms, and potential for early intervention. COPD 2008; 5: 235-256; https://journal.pulmonology.ru/pulm/article/view/1717

الاتاحة: https://journal.pulmonology.ru/pulm/article/view/1717
https://doi.org/10.18093/0869-0189-2010-6-51-59

المؤلفون: М. М. Илькович, А. Л. Акопов

المصدر: PULMONOLOGIYA; № 1 (2009); 118-119 ; Пульмонология; № 1 (2009); 118-119 ; 2541-9617 ; 0869-0189 ; 10.18093/0869-0189-2009-0-1

وصف الملف: application/pdf

Relation: https://journal.pulmonology.ru/pulm/article/view/1746/1184; https://journal.pulmonology.ru/pulm/article/view/1746; undefined

الاتاحة: https://journal.pulmonology.ru/pulm/article/view/1746